

Manuscript version: Author's Accepted Manuscript

The version presented in WRAP is the author's accepted manuscript and may differ from the published version or Version of Record.

Persistent WRAP URL:

<http://wrap.warwick.ac.uk/116366>

How to cite:

Please refer to published version for the most recent bibliographic citation information. If a published version is known of, the repository item page linked to above, will contain details on accessing it.

Copyright and reuse:

The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions.

Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Publisher's statement:

Please refer to the repository item page, publisher's statement section, for further information.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk.

1
2
3 **Iterative arylation of itaconimides with diazonium salts through electrophilic Palladium**
4
5 **catalysis: divergent β -H-elimination pathways in repetitive Matsuda-Heck reactions**
6
7
8
9


10 Nastja Riemer,^{a,b} Michael Shipman,^b Pablo Wessig^a and Bernd Schmidt^{a*}

11
12 ^aUniversitaet Potsdam, Institut fuer Chemie, Karl-Liebknecht-StraÙe 24-25, D-14476 Potsdam-
13
14 Golm, Germany

15
16
17 ^bDepartment of Chemistry, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL,
18
19 U.K.

20
21
22
23
24 e-mail: bernd.schmidt@uni-potsdam.de

25
26
27
28 **Table of contents graphic:**



49 **Abstract:** *N*-Arylitaconimides, accessible from maleic anhydride, anilines and
50 paraformaldehyde, react with arene diazonium salts in a Pd-catalyzed Matsuda-Heck arylation
51 to the pharmacologically relevant *E*-configured 3-arylmethylidene pyrrolidine-2,5-diones (also
52 known as arylmethylidene succinimides) through an *exo*-selective β -H-elimination. The
53 coupling proceeds at ambient temperature with the simple and easy-to-handle precatalyst Pd-
54 II-acetate under ligand- and base-free conditions. Notable features are high isolated yields as
55
56
57
58
59
60

1
2
3 well as regio- and stereoselectivities, and short reaction times. In a comparative investigation,
4 aryl iodides, bromides and triflates were shown to be inferior coupling reagents in this reaction.
5
6 The 3-arylmethylidene pyrrolidine-2,5-diones undergo a second Matsuda-Heck coupling,
7
8 which proceeds via an *endo*-selective β -H-elimination to give diarylmethyl substituted
9
10 maleimides as coupling products. These products can also be accessed in one flask by sequential
11
12 addition of different arene diazonium salts to the starting itaconimide. The potential of 3-
13
14 arylmethylidene succinimides as photoswitches was tested. Upon irradiation of the *E*-isomer at
15
16 300 nm partial isomerization to the *Z*-isomer ($E : Z = 65 : 35$ in the photostationary state) was
17
18 observed. The isomerization was found to be nearly completely reversible by irradiating the
19
20 mixture at 400 nm.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

3-Arylmethylidene pyrrolidine-2,5-diones of the general formula *exo-1* have found diverse applications (**Figure 1**). Compounds *exo-1bu* and *exo-1bv*,¹ for example, were tested as inhibitors of the type 2 5 α -reductase (T2-5 α -reductase), an enzyme responsible for the reduction of testosterone to the more potent androgen dihydrotestosterone.^{1,2} Inhibitors of T2-5 α -reductase, such as the clinically used drug finasteride, are potentially useful for the treatment of benign prostate hyperplasia.^{3,4} The 3-arylmethylidene pyrrolidine-2,5-dione *exo-1ae* has been investigated with regard to its vasorelaxant activity, which was reported to be in the range of the standard drug doxazosin.⁵ Compounds of the general formula *exo-1* have been used as Michael acceptors for irreversible, site-specific thiol bioconjugation,⁶ as test substrates for asymmetric transformations,⁷⁻⁹ and as starting materials to access other heterocyclic systems, such as pyrolo quinolines¹⁰ or coumarins.¹¹ Recently, 3-arylmethylidene pyrrolidine-2,5-diones were investigated as reactants in multicomponent reactions for the synthesis of several interesting spirocyclic scaffolds.¹²⁻¹⁵ Hydrogenation of compounds *exo-1* leads to 3-benzyl succinimides, which are also an important structural pattern in medicinal chemistry. For example, compound **2** was identified as an inhibitor of the leukocyte common antigen-related phosphatase, a potential target for the treatment of neurological diseases.¹⁶ By using Ir-catalysts in combination with chiral biphenyl-oxazoline-phosphine ligands the hydrogenation of compounds *exo-1* to 3-benzyl succinimides can be achieved with very high levels of enantioselectivity.⁷





Figure 1. Structures of biologically relevant 3-arylmethylidene-pyrrolidine-2,5-diones *exo-1* and a 3-benzylsuccinimide **2**.

Almost all syntheses of 3-arylmethylidene pyrrolidine-2,5-diones *exo-1* reported in the literature use a phospho-Michael-addition / Wittig-olefination sequence. This route, originally developed by Hedaya and Theodoropoulos as a two-step synthesis,¹⁷ starts from maleimides **3** which react with phosphines in a conjugate addition / tautomerization reaction to ylides **4**. These undergo a Wittig-olefination with aromatic aldehydes in the second step (**Scheme 1a**). Although several modifications and improvements, including a catalytic variant,¹⁸ have been published since the original report,^{6,19-23} some disadvantages of this approach remain: in general, elevated temperatures and protic solvents are required to achieve useful levels of conversion, which may affect hydrolytic stability of the succinimide structure;²⁴ the required benzaldehydes are sometimes prone to oxidation and need to be purified beforehand; other carbonyl groups that may also undergo Wittig olefination reactions are not tolerated; the inevitable formation of stoichiometric amounts of phosphine oxides can hamper product isolation and purification if the 3-arylmethylidene pyrrolidine-2,5-diones have similar polarity.

Scheme 1. Phospha-Michael addition / Wittig-olefination (previous routes)
vs. Matsuda-Heck route (this work).



In continuation of our previous investigations²⁵⁻²⁷ into the development and application of Matsuda-Heck reactions,²⁸ i. e. the Pd-catalyzed Heck-type coupling of arene diazonium salts with alkenes,²⁹⁻³⁶ we wondered whether an alternative approach to 3-arylmethylidene pyrrolidine-2,5-diones *exo-1* that starts from itaconimides **5** and stable and isolable arene diazonium salts **6** might be a competitive or even advantageous alternative to the phospha-Michael-addition / Wittig-olefination approach. Important questions to be answered in this context are: will the final β -H-elimination step³⁶ leading to the liberation of the coupling products proceed *exo*- or *endo*-selectively (i. e. to *exo-1* or to *endo-1*), or to a mixture of *exo*- and *endo*-isomers? Is it possible to identify conditions for selective single and double arylations, and will the double arylation products **7** be formed as *exo*- or *endo* isomers? (**Scheme 1b**).


Literature precedence on Heck-arylation approaches to *exo*-arylmethylidene-pyrrolidine-2,5-diones and related lactams is scarce: we are aware of an intramolecular Heck-reaction with an aryl iodide for the synthesis of tetrahydroquinoline derivatives that were tested for their anti-hyperalgesic activity³⁷ and of an intermolecular Heck reaction between aryl iodides and *exo*-methylene lactams as a route to benzyl- and benzylidene pyrrolizidinones.³⁸ Heck reactions of

1
2
3 maleimides **3** with aryl iodides give the expected 3-arylmaleimides, but were found to be
4
5 challenging due to increased hydrolysis of the products at elevated temperatures and prolonged
6
7 reaction times.²⁴ These obstacles were overcome by the development of special reaction
8
9 conditions for the Pd-catalyzed coupling. For a single example these conditions were applied
10
11 to a 3-methylmaleimide, resulting in the formation of a 3-arylmethylidene-2,5-dione of the
12
13 general formula **1** rather than the expected 3-methyl-4-arylmaleimide. The formation of the
14
15 unexpected *exo*-arylmethylidene product was explained by a Pd-catalyzed isomerization of the
16
17 3-methylmaleimide to an itaconimide **5**, which subsequently undergoes a Heck-reaction.
18
19
20
21
22
23

24 Results and discussion


25
26 **Synthesis of *N*-arylitaconimides **5**.** As a test substrate for the development and optimization
27
28 of the envisaged Matsuda-Heck-coupling *N*-phenylitaconimide (**5a**) was chosen. This
29
30 compound³⁹ was, like a number of other *N*-arylitaconimides such as **5b**,⁴⁰ previously
31
32 synthesized from itaconic anhydride and anilines in a two-step ring-opening / cyclizative
33
34 condensation sequence. Recently, this method was further developed into a one-flask synthesis
35
36 by using improved conditions for the cyclizative condensation and applied to the synthesis of
37
38 **5a** and several other *N*-arylitaconimides.⁴¹ We synthesized **5a** from *N*-phenylmaleimide (**3a**)
39
40 and paraformaldehyde by adaptation of the phospho-Michael-addition / Wittig-olefination
41
42 sequence.⁹ The yield is virtually identical to that reported for the itaconic anhydride route
43
44 outlined above,⁴¹ and the potential separation and purification problems were not observed for
45
46 this particular derivative (**Scheme 2**).
47
48
49
50

51 **Scheme 2.** Synthesis of *N*-phenylitaconimide (**5a**).



With a view to the synthesis of the T2-5 α -reductase inhibitors *exo*-**1bu** and *exo*-**1bv** (**Figure 1**) we also synthesized *N*-(3-hydroxyphenyl)itaconimide (**5b**)⁴⁰ by using the tandem phosphamichael / Wittig-olefination method. To this end maleic anhydride was first reacted with 3-hydroxyaniline (**9**) to furnish the *N*-arylmaaleimide **3b**,⁴² which was then converted to **5b** with paraformaldehyde and triphenylphosphine in 65% yield over two steps (**Scheme 3**).

Scheme 3. Synthesis of *N*-(3-hydroxyphenyl)itaconimide (**5b**).




Optimized coupling conditions for arene diazonium salts and alternative coupling

partners. The conditions for the Matsuda-Heck coupling were optimized for the reaction of *N*-phenylitaconimide (**5a**) and 4-methoxybenzenediazonium salt **6a** (**Table 1**). In the first experiments, equimolar ratios of both coupling partners were used. The most important variables in Matsuda-Heck reactions are the precatalyst, the solvent and the presence (or absence) of a base. In many cases good results can be obtained by using Pd(OAc)₂ as a precatalyst without additional ligands. Donor ligands often have detrimental effects on the stability of the arene diazonium salts and on the overall reactivity and should therefore be avoided.^{29,43,44} Some controversy exists about the influence of bases on Matsuda-Heck reactions. Matsuda and coworkers routinely used NaOAc in their pioneering studies,⁴⁵ but later investigations revealed that addition of this base has no or even negative effects on the rate of the reaction and on the yield.²⁹ However, in our previous studies we found examples for both beneficial and detrimental effects of adding NaOAc, depending on the arene diazonium salt,

the olefin and the solvent used.⁴⁶ Routinely tested solvents in Matsuda-Heck reactions are acetonitrile, which is known to stabilize the catalytically active species through coordination,⁴⁷ and methanol.³⁰

Table 1. Optimization of Matsuda-Heck coupling conditions.



entry	solvent ^{a)}	NaOAc (equiv.)	T/° C	5a (equiv.)	Conversion ^{b)}	<i>exo</i> - 1aa (yield) ^{c)}	<i>endo</i> - 7aa (yield) ^{c)}
1	CH ₃ CN	--	20	1.0	incomplete	n. d.	n. d.
2	CH ₃ CN	4.0	20	1.0	incomplete	n. d.	n. d.
3	methanol	--	20	1.0	quantitative	72	26
4	methanol	4.0	20	1.0	traces	n. d.	n. d.
5	methanol	--	-23	1.0	quantitative	83	10
6	methanol	--	-23	1.2	quantitative	94	n. d.
7	methanol	--	20	1.2	quantitative	95	n. d.
8 ^{d)}	methanol	--	20	0.33	quantitative	n. d.	65

^{a)}Initial concentration of diazonium salt **6a**: 0.0625 M. ^{b)}Qualitatively determined by TLC.

^{c)}Isolated yields; n. d.: not determined. ^{d)}Initial concentration of diazonium salt **6a**: 0.0938 M; reaction time 18 h.

In acetonitrile the formation of a Matsuda-Heck coupling product was observed both under basic and under base-free conditions, but the conversion remained incomplete (entries 1, 2). In

1
2
3 methanol the addition of NaOAc resulted in a nearly complete inhibition of the coupling
4
5 reaction (entry 4), whereas the arene diazonium salt was rapidly and quantitatively consumed
6
7 under base-free conditions (entry 3). From this reaction mixture two coupling products *exo-1aa*
8
9 and *endo-7aa* could be isolated in 72% and 26% yield.

10
11
12 Compound *exo-1aa* was identified by comparison of its NMR-data with those reported in the
13
14 literature²¹ and additionally the assigned structure was corroborated by 2D-NOE spectroscopy.

15
16 A strong NOE between the *ortho*-H of the 4-methoxyphenyl substituent and the CH₂ group
17
18 supports the assigned *exo-E*-structure. Compound *endo-7aa* has not been described in the
19
20 literature but could easily be distinguished from the alternative *exo*-isomer, because only one
21
22 set of signals with double intensity was observed for all protons and carbons of the 4-
23
24 methoxyphenyl substituent, and two singlets for the methine proton and the proton at position
25
26 4 of the heterocycle were observed.

27
28
29 In an attempt to suppress the formation of the double Matsuda-Heck product *endo-7aa* the
30
31 reaction temperature was lowered to -23 °C. The selectivity towards *exo-1aa* was indeed
32
33 notably improved, but we could still isolate 10% of *endo-7aa* (entry 5). In the next step, we
34
35 increased the amount of itaconimide **5a** to 1.2 equivalents while keeping the reaction
36
37 temperature at -23 °C. Compound *exo-1aa* was isolated in 94% yield, without the formation of
38
39 any double arylation product (entry 6). Virtually the same result was obtained at ambient
40
41 temperature under otherwise identical conditions (entry 7). In all cases the reaction was
42
43 complete within 30 minutes. We noted that, in contrast to the starting materials **5a** and **6a**, the
44
45 Matsuda-Heck product *exo-1aa* is only sparingly soluble in methanol at the chosen initial
46
47 substrate concentration of 0.0625 mol•L⁻¹. This allowed us to readily isolate the product by
48
49 filtration. Additional purification by chromatography is normally not required.


50
51
52 The double Matsuda-Heck product *endo-7aa* was selectively synthesized in 65% yield by using
53
54 three equivalents of the arene diazonium salt **6a** in methanol at a higher initial concentration of
55
56
57
58
59
60

1
2
3 0.0938 M and a reaction time of 18 h. Under these conditions we could not detect any mono
4
5 aryl product *exo-1aa* (entry 8).

6
7 Although arene diazonium salts are generally considered to be more reactive electrophilic
8
9 coupling partners in Pd-catalyzed reactions, systematic comparative investigations to prove this
10
11 superior reactivity are rare. For these reasons we investigated Mizoroki-Heck reactions of
12
13 itaconimide **5a** with 4-methoxybenzenes bearing iodide (**8a**), triflate (**8b**) or bromide (**8c**) as
14
15 leaving groups (**Table 2**). Optimal reaction conditions for the coupling of these reagents with
16
17 electron deficient alkenes are known to differ significantly from the preferred conditions for
18
19 arene diazonium salts, as can be seen from a recent comprehensive literature survey.⁴⁸ For these
20
21 reasons we did not include the optimized conditions for the Matsuda-Heck coupling of **5a** and
22
23 **6a** (Table 1, entry 7) in this comparative investigation, but chose previously established reaction
24
25 conditions for the coupling of acyclic electron deficient alkenes⁴⁸ and *exo*-methylene γ -
26
27 lactones⁴⁹ with aryl halides and triflates as general guidance. Such conditions normally involve
28
29 the use of DMF as a solvent at elevated reaction temperatures, reaction times of several hours,
30
31 triethylamine as a base, an excess of the electrophilic coupling partner and very often activating
32
33 phosphine ligands. In a first experiment 4-methoxyiodobenzene (**8a**) was reacted with
34
35 itaconimide **5a** in DMF at 90 °C, using Pd(OAc)₂ as a precatalyst without addition of an
36
37 activating phosphine ligand (entry 1). Although **8a** was used in excess (1.2 equivalents) we did
38
39 not observe the formation of any double arylation product, but isolated *exo-1aa* in 60% yield
40
41 as the only product. Monitoring the reaction by TLC revealed that long reaction times are indeed
42
43 required to achieve a synthetically useful conversion. By addition of tri-*o*-tolylphosphine as a
44
45 ligand under otherwise identical conditions the yield of *exo-1aa* could be increased to 70%, but
46
47 we still did not detect any double arylation product (entry 2). In a third experiment we could
48
49 show that elevated reaction temperatures are necessary, because at ambient temperature no
50
51 conversion was observed and both starting materials were recovered unchanged (entry 3).
52
53 Applying the conditions of entry 2 to the triflate **8b** resulted in a very low yield of 26% (entry
54
55
56
57
58
59
60

4). For the bromide **8c** sodium acetate-trihydrate was tested as an alternative base (entry 5). In this case an even higher temperature of 140 °C was necessary, but the reaction was still very slow compared to the analogous diazonium salt.

Table 2. Comparative investigation of alternative coupling partners **8**.



entry	8	X	Ligand (mol %)	Base (equiv.)	T (° C)	t (h)	Yield of <i>exo-1aa</i> (%)
1	8a	I	--	NEt ₃ (3.0)	90	18	60
2	8a	I	P(<i>o</i> -tolyl) ₃ (10)	NEt ₃ (3.0)	90	18	70
3	8a	I	P(<i>o</i> -tolyl) ₃ (10)	NEt ₃ (3.0)	20	18	-- ^{a)}
4	8b	OTf	P(<i>o</i> -tolyl) ₃ (10)	NEt ₃ (3.0)	90	18	26
5	8c	Br	P(<i>o</i> -tolyl) ₃ (10)	NaOAc•3H ₂ O (1.0)	140	1	21


^{a)}No conversion.

In summary, these experiments clearly prove that arene diazonium salts are significantly more reactive in this coupling reaction than aryl iodides, and that aryl triflates and bromides can not be used to synthesize *exo*-arylmethylidene-2,5-diones in preparatively useful yields.

Scope of Matsuda-Heck coupling reactions with itaconimides. The optimized conditions for Matsuda-Heck reactions of *N*-phenylitaconimide (**5a**) (Table 1, entry 7) were in the next step applied to the coupling of **5a** with various arene diazonium salts **6b-t** (Table 3, entries 2 – 20). From these examples only the coupling reaction with 2-nitrobenzene diazonium salt **6q** fails completely and results in the formation of a complex mixture of products (entry 17). Notably, with 2-bromobenzene diazonium salt **6p** the coupling product *exo-1ap* was obtained in 72%

yield in which the bromine atom is unscathed. All other arene diazonium salts **6** tested in this transformation reacted to the expected 3-arylmethylidene-2,5-pyrrolidinediones *exo-1* in very good to excellent yields and perfect regio- and stereoselectivities. These examples also include the vasorelaxant agent *exo-1ae*⁵ (entry 5). For the synthesis of the T2-5 α -reductase inhibitors *exo-1bu* and *exo-1bv*¹ (**Figure 1**) *N*-(3-hydroxyphenyl)itaconimide (**5b**) was coupled with diazonium salts **6u** (entry 21) and **6v** (entry 22), respectively, under the same optimized conditions.

Table 3. Scope of Matsuda-Heck reactions with itaconimides **5a,b**.



entry	5	R	6	R ¹	R ²	R ³	R ⁴	<i>exo-1</i>	Yield (%)
1	5a	H	6a	OCH ₃	H	H	H	<i>exo-1aa</i>	95
2	5a	H	6b	OBn	H	H	H	<i>exo-1ab</i>	81
3	5a	H	6c	OH	H	H	H	<i>exo-1ac</i>	92
4	5a	H	6d	F	H	H	H	<i>exo-1ad</i>	91
5	5a	H	6e	Cl	H	H	H	<i>exo-1ae</i>	91
6	5a	H	6f	Br	H	H	H	<i>exo-1af</i>	93
7	5a	H	6g	CN	H	H	H	<i>exo-1ag</i>	86
8	5a	H	6h	C(O)CH ₃	H	H	H	<i>exo-1ah</i>	94
9	5a	H	6i	NHAc	H	H	H	<i>exo-1ai</i>	90
10	5a	H	6j	NO ₂	H	H	H	<i>exo-1aj</i>	89
11	5a	H	6k	H	H	H	H	<i>exo-1ak</i>	88
12	5a	H	6l	H	CH ₃	H	H	<i>exo-1al</i>	quant.
13	5a	H	6m	H	CN	H	H	<i>exo-1am</i>	89

14	5a	H	6n	H	H	OCH ₃	H	<i>exo-1an</i>	87
15	5a	H	6o	H	H	F	H	<i>exo-1ao</i>	99
16	5a	H	6p	H	H	Br	H	<i>exo-1ap</i>	72
17	5a	H	6q	H	H	NO ₂	H	<i>exo-1aq</i>	-- ^{a)}
18	5a	H	6r	OH	Br	H	H	<i>exo-1ar</i>	95
19	5a	H	6s	OH	CO ₂ CH ₃	H	H	<i>exo-1as</i>	93
20	5a	H	6t	OCH ₃	OCH ₃	H	OCH ₃	<i>exo-1at</i>	90
21	5b	OH	6u	H	NO ₂	H	H	<i>exo-1bu</i>	79
22	5b	OH	6v	Cl	H	Cl	H	<i>exo-1bv</i>	96

^{a)}complex mixture of products.

Iterative Matsuda-Heck coupling. In the course of our investigation into the optimization of the Matsuda-Heck coupling (**Table 1**, entry 3) we noted that a considerable amount of the β,β -diarylation product *endo-7aa* is obtained if itaconimide **5a** and diazonium salt **6a** are used in an equimolar ratio. This product can even be synthesized selectively at ambient temperature by using three equivalents of the arene diazonium salt and prolonged reaction times (**Table 1**, entry 8). These results are remarkable, because β,β -diarylation reactions of electron deficient olefins are by no means facile processes. This is for instance underlined by our observation that during the analogous Mizoroki-Heck couplings (**Table 2**) no β,β -diarylation products were detected, although the aryl halides were used in excess and the reactions were conducted at elevated temperatures over long reaction times. A survey of pertinent literature confirms that Heck-type β,β -diarylation reactions of terminal alkenes or arylation reactions of α,β -disubstituted alkenes such as cinnamic acid derivatives indeed require much more forcing conditions (elevated temperatures, long reactions times, elaborate bases and ligands) than the monoarylation of electron deficient terminal alkenes.⁵⁰⁻⁵⁶ Analogous Matsuda-Heck couplings have scarcely been

1
2
3 reported in the literature: Konno et al.⁵⁷ and Cacchi et al.⁵⁸ described successful Matsuda-Heck
4 reactions of electron deficient acyclic olefins with aliphatic substituents in the β -position, and
5
6 Taylor and Correia reported the stereoselective β -arylation of cinnamates.⁵⁹ Very recently,
7
8 Lucks and Brunner found that a heterogeneous catalyst system of Pd immobilized on AlPO₄ is
9 particularly reactive in the β,β -diarylation of acrylates and a few other electron deficient
10 alkenes.³⁵ In all these examples modifications of the standard reaction conditions for Matsuda-
11 Heck couplings of electron deficient olefins were required, such as elevated reaction
12 temperatures^{35,57,58} or the use of less common methanol-acetonitrile solvent mixtures in
13 combination with a base.⁵⁹ In light of this literature precedence we thought that the facile
14 formation of the double arylation product *endo-7aa* at ambient temperature deserves further
15 attention and investigated the scope of a repetitive Matsuda-Heck coupling, starting from
16 various 3-arylmethylidene pyrrolidine-2,5-diones *exo-1* and arene diazonium salts **6**. A
17 potential obstacle for the development of a repetitive coupling reaction was observed during
18 the optimization study of the first arylation step and the investigation into the scope of the
19 Matsuda-Heck reaction with *N*-arylitaconimides. The products *exo-1* are, in contrast to the *N*-
20 arylitaconimides **5** and the arene diazonium salts **6**, in general sparingly soluble in methanol at
21 the concentrations routinely used for the coupling step and precipitate from the solution. While
22 this facilitates the purification of the coupling products, as outlined above, it might impede a
23 second arylation. For these reasons we started this part of the investigation with solubility tests,
24 in order to identify a solvent that would allow us to conduct the second coupling under
25 homogeneous reaction conditions. To this end, the envisaged starting material *exo-1aa* (15 mg,
26 corresponding to 5.7 μmol) was mixed with 0.5 mL of various solvents at ambient temperature,
27 which would result in a concentration of ca. 0.11 mol•L⁻¹ if the starting material dissolves
28 completely. Among the solvents tested this is only the case for hexafluoroisopropanol (HFIP)
29 and 1,4-dioxane, whereas in methanol, ethanol, 2-propanol, 1-butanol, acetonitrile, ethyl acetate
30 and THF substantial amounts of *exo-1aa* remain undissolved. Repeating the solubility tests with
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1.0 mL of these solvents (corresponding to an initial starting material concentration of 0.057 mol·L⁻¹), THF also produced a homogeneous solution. The three solvents HFIP, 1,4-dioxane and THF were then tested in the Matsuda-Heck coupling of **5a** and **6a** under basic as well as base-free conditions (**Table 4**).

Table 4. Screening of alternative solvents for the Matsuda-Heck coupling of **5a** and **6a**.^{a)}

entry	Solvent ^{b)}	NaOAc (equiv.)	Result ^{c)}
1	(CF ₃) ₂ CHOH	--	trace amounts of <i>exo-1aa</i>
2	(CF ₃) ₂ CHOH	4.0	trace amounts of <i>exo-1aa</i>
3	1,4-dioxane	--	incomplete conversion to <i>exo-1aa</i>
4	1,4-dioxane	4.0	incomplete conversion to <i>exo-1aa</i>
5	THF	--	incomplete conversion to <i>exo-1aa</i>
6	THF	4.0	trace amounts of <i>exo-1aa</i>

^{a)}Itaconimide **5a** used in excess (1.2 equiv.). ^{b)}Initial substrate concentration 0.0625 M. ^{c)}Qualitative assessment; reactions monitored by TLC.

In HFIP (entries 1, 2) only trace amounts of the Matsuda-Heck product *exo-1aa* were detected by TLC in the presence and in the absence of NaOAc. In 1,4-dioxane (entries 3, 4) notable conversion to the product was observed under basic as well as base-free conditions, but considerable amounts of unreacted starting material **5a** were also detected. The same result was obtained with THF in the absence of NaOAc (entry 5), whereas in the presence of the base only trace amounts of the product were detected on TLC (entry 6). For these reasons we returned to methanol as a solvent for the second Matsuda-Heck reaction, but used a lower initial substrate concentration than for the Matsuda-Heck arylation of itaconimides **5**.

The reaction of *exo-1aa* with arene diazonium salt **6a** furnished under these standard conditions the diaryl product *endo-7aa* in 86% yield (**Table 5**, entry 1). Hence, the overall yield for this two-step synthesis of *endo-7aa* from *N*-phenyl itaconimide **5a** is 81%. This is substantially higher than the 65% yield obtained for the one-pot double arylation of **5a** with **6a** (**Table 1**,

1
2
3 entry 8). Compound *exo-1aa* was coupled in a comparable yield of 83% with the *p*-chloro
4 substituted arene diazonium salt **6e** to the diarylated product *endo-7ae* (entry 2). Interestingly,
5 the reaction of the *p*-chlorobenzylidene succinimide *exo-1ae* with the *p*-methoxy substituted
6 arene diazonium salt **6a**, which would give the same product *endo-7ae*, fails completely (entry
7 3). The unsubstituted benzylidene succinimide *exo-1ak*, however, reacts with the same
8 diazonium salt **6a** to the product *endo-7ka* in a somewhat lower, but still synthetically useful
9 yield (entry 4). The highest yields were obtained for the trimethoxybenzylidene substituted
10 succinimide *exo-1at* and diazonium salts **6a** and **6e**, which react to the products *endo-7ta* and
11 *endo-7te*, respectively, in nearly quantitative yields (entries 5, 6). These observations suggest
12 that more electron rich arylmethylidene units facilitate the second Matsuda-Heck arylation, a
13 conclusion that has previously been drawn by Taylor and Correia in the course of their
14 investigation into Matsuda-Heck couplings of cinnamates.⁵⁹ We then investigated Matsuda-
15 Heck couplings of the trimethoxybenzylidene succinimide *exo-1at* with several other arene
16 diazonium salts **6** (entries 7 – 12). The reaction fails only for the *p*-acetyl substituted arene
17 diazonium salt **6h** (entry 8), whereas all other diazonium salts tested undergo a coupling with
18 *exo-1at*, albeit in yields lower than those obtained with the diazonium salts **6a** and **6e**. With the
19 *m*-nitro substituted arene diazonium salt **6u** conversion remains incomplete and unidentified
20 side products are formed. Purification of the coupling product *endo-7tu* is difficult due to very
21 similar polarities and could only be achieved with significant loss of yield (entry 10). An
22 interesting exception in this series is the reaction of *exo-1at* and the *p*-nitro substituted arene
23 diazonium salt **6j** (entry 9 and **Figure 2**). For this combination quantitative conversion was
24 observed, but the reaction was rather sluggish and gave the *exo*-coupling products *E*- and *Z*-
25 *exo-7tj* in a ratio of 4 : 1 as an inseparable mixture, which was contaminated with several
26 unidentified byproducts. Assignment of the *E*-configuration to the major isomer is based on
27 2D-NOE-spectroscopy.





Figure 2. Structures of *E*- and *Z*-*exo*-**7tj** and indicative NOE-interaction.

Table 5. Scope of iterative Matsuda-Heck coupling.




entry	<i>exo</i> - 1	R ¹	R ²	R ³	6	R ⁴	R ⁵	<i>endo</i> - 7	Yield (%)
1	<i>exo</i> - 1aa	OCH ₃	H	H	6a	OCH ₃	H	<i>endo</i> - 7aa	86
2	<i>exo</i> - 1aa	OCH ₃	H	H	6e	Cl	H	<i>endo</i> - 7ae	83
3	<i>exo</i> - 1ae	Cl	H	H	6a	OCH ₃	H	<i>endo</i> - 7ea	-- ^{a,b}
4	<i>exo</i> - 1ak	H	H	H	6a	OCH ₃	H	<i>endo</i> - 7ka	74
5	<i>exo</i> - 1at	OCH ₃	OCH ₃	OCH ₃	6a	OCH ₃	H	<i>endo</i> - 7ta	96
6	<i>exo</i> - 1at	OCH ₃	OCH ₃	OCH ₃	6e	Cl	H	<i>endo</i> - 7te	95
7	<i>exo</i> - 1at	OCH ₃	OCH ₃	OCH ₃	6f	Br	H	<i>endo</i> - 7tf	42
8	<i>exo</i> - 1at	OCH ₃	OCH ₃	OCH ₃	6h	C(O)CH ₃	H	<i>endo</i> - 7th	-- ^a
9	<i>exo</i> - 1at	OCH ₃	OCH ₃	OCH ₃	6j	NO ₂	H	<i>exo</i> - 7tj	96 ^c
10	<i>exo</i> - 1at	OCH ₃	OCH ₃	OCH ₃	6u	H	NO ₂	<i>endo</i> - 7tu	10 ^d
11	<i>exo</i> - 1at	OCH ₃	OCH ₃	OCH ₃	6r	OH	Br	<i>endo</i> - 7tr	59
12	<i>exo</i> - 1at	OCH ₃	OCH ₃	OCH ₃	6s	OH	CO ₂ CH ₃	<i>endo</i> - 7ts	27

^a)No conversion. ^b)*endo*-**7ea** and *endo*-**7ae** are identical. ^c)Product *exo*-**7tj** was obtained as a mixture of *E*- and *Z*-isomers (*E* : *Z* = 4 : 1, determined by ¹H NMR spectroscopy) and minor amounts of unidentified byproducts. ^d)Low yield is caused by loss of material during purification.

To conclude this part of the study we investigated the possibility of performing sequential Matsuda-Heck arylations in a one-flask reaction. To this end *N*-phenyl itaconimide (**5a**) was first reacted with diazonium salt **6a** using the optimized conditions for a monoarylation. The reaction mixture was then diluted by addition of methanol, and the second arene diazonium salt **6e** was added. Pleasingly, the double arylation product *endo*-**7ae** was isolated in 69% yield (**Scheme 4**).

Scheme 4. Repetitive one-flask Matsuda-Heck arylation of itaconimide **5a**.




A comment on regioselectivity of the iterative Matsuda-Heck arylations. We are currently unable to provide conclusive explanations for the different regioselectivities of the iterative arylation steps. Mechanistic scenarios must take into account that the regioselectivity of Heck-type reactions may arise from kinetic or thermodynamic control. Thermodynamic control requires a sufficiently stable Pd-hydride from the β -H-elimination step, which catalyzes a subsequent double bond migration through a hydropalladation/ β -H-elimination cycle (“chain walking” mechanism)⁶⁰⁻⁶² or through a 1,2-dyotropic shift followed by a β -H-elimination.⁶³ This scenario is sometimes referred to as “post-Mizoroki-Heck double-bond migration”⁶⁴ and it can be provoked by adding stabilizing ligands, e. g. chloride, to the reaction mixture (Jeffery-conditions).⁶² In the case of Matsuda-Heck reactions cationic Pd-species are proposed as intermediates, unless strongly coordinating anionic bases or counterions are present.⁴⁷ The cationic Pd-hydrides resulting from the β -H-elimination step are destabilized by the positive

1
2
3 charge, and consequently virtually no subsequent double bond migration occurs, as shown by
4
5 Correia and co-workers for the Matsuda-Heck reaction of 2,3-dihydrofuran.⁴⁷ Although this
6
7 does exclude the possibility of post-Matsuda-Heck isomerizations completely, they are rather
8
9 unlikely. Under kinetic control the regioselectivity of Heck-type reactions is determined during
10
11 the β -H-elimination step⁶⁵ and can be biased by electronic effects in the substrate,⁶⁶ through
12
13 catalyst control^{36,67} or by conformational constraints.²⁶ To proceed efficiently, these
14
15 eliminations normally require a H^{β} -C-C-Pd dihedral angle close to 0° (*syn*- β -hydride
16
17 elimination) and a vacant coordination site at the transition metal,^{68,69} because *syn*- β -hydride
18
19 eliminations are initiated by an agostic interaction between the β -C-H bond and the metal.⁷⁰ For
20
21 the example of the iterative Matsuda-Heck arylation of *N*-phenylitaconimide **5a** and diazonium
22
23 salts **6a** in the first and **6e** in the second step the following mechanistic scenario unfolds
24
25 (**Scheme 5**): the first Matsuda-Heck arylation starts with a carbopalladation (migratory
26
27 insertion) of the C-C-double bond of **5a** to give initially the Pd- σ -complex **8a**, which can then
28
29 undergo rotation around the *exo*-C-C-bond to access two *syn*-conformations suitable for *exo*- β -
30
31 H-elimination. The experimentally observed product *E*-*exo*-**1aa** would result from conformer
32
33 **8b**, whereas formation of *Z*-*exo*-**1aa** would require a β -H-elimination from conformer **8c**. If the
34
35 dihedral angle between Pd and the *syn*-*endo*-H is sufficiently small, β -H-elimination could also
36
37 lead to the maleimide *endo*-**1aa**. The second Matsuda-Heck reaction starts with a
38
39 carbopalladation of the *exo*-double bond of *E*-*exo*-**1aa** to furnish the Pd- σ -complex **10a**.
40
41 Clockwise or counterclockwise rotation around the *exo*-C-C-bond is now required to bring the
42
43 *exo*-H and Pd into a *syn*-orientation (conformer **10b**), from which β -H-elimination may occur
44
45 to yield *E*- and *Z*-*exo*-**7ae**. In contrast, formation of the experimentally exclusively observed
46
47 product *endo*-**7ae** must proceed through β -elimination of the *syn*-*endo*-H, unless it is formed
48
49 via a post-Matsuda-Heck double bond migration as outlined above.⁷¹ In future investigations
50
51 we plan a complete analysis of the catalytic cycle, with a focus on the different β -H-elimination
52
53
54
55
56
57
58
59
60


pathways, based on DFT-calculations. DFT-methods have previously been used to gain a deeper insight into the mechanism of Matsuda-Heck reactions, e. g. with a view towards rationalizing *E/Z*-selectivity,⁷² understanding the role of catalyst stabilizing additives,⁷³ or the origin of enantiocontrol in asymmetric Matsuda-Heck reactions.^{74,75}

Scheme 5. Formation of regio- and stereoisomeric Matsuda-Heck-products.

First Matsuda-Heck arylation:



Second Matsuda-Heck arylation:



Investigation into the photochemically induced *E/Z*-isomerization of 3-arylmethylidene succinimides *exo*-1. The photochemically triggered *E/Z*-isomerization of double bonds is one of the most important functional principles of molecular switches.⁷⁶ Because biological and biochemical studies are the main area of application of these switches, a long-wave excitation (ideally in the visible range) is desirable. Besides azobenzenes⁷⁷ highly substituted olefins are potential candidates for photoswitches. In this context we were interested to find out whether


compounds *exo-1* could also be suitable as photoswitches. First we qualitatively investigated the photophysical and photochemical behaviour of the five derivatives *exo-1ac*, *exo-1an*, *exo-1ar*, *exo-1as* and *exo-1at*. All of these compounds exhibit a broad absorption band between 300 and 350 nm in the UV spectrum (**Table 6**).

Table 6. UV-Absorption maxima of compounds **1** in acetonitrile

entry	<i>exo-1</i>	λ_{\max} [nm] ^{a)}	lg ϵ ^{b)}	λ_{PSS} [nm] ^{c)}
1	<i>exo-1ac</i>	320	4.499	324
2	<i>exo-1an</i>	330	4.045	328
3	<i>exo-1ar</i>	315	4.396	321
4	<i>exo-1as</i>	307	4.496	309
5	<i>exo-1at</i>	319	4.366	323

^{a)}Before excitation. ^{b)} ϵ in L•mol⁻¹•cm⁻¹. ^{c)}After excitation (PSS)

When irradiated with relatively intensive UV light (500 W Hg arc lamp, edge filter > 295 nm, acetonitrile) they underwent a non-specific decomposition. If, on the other hand, these compounds were exposed to narrow-band UV-B light (interference filter 300 nm / edge filter > 295 nm) a partial *E* → *Z*-isomerisation was observed. This is indicated by a small bathochromic shift (4-6 nm) of the absorption maximum (except *exo-1an*) and very weakly increased absorption above 400 nm in the UV spectra. Furthermore, the occurrence of some isosbestic points in the irradiation spectra proves a selective A → B-reaction.⁷⁸ The absorption maxima in the photostationary state (λ_{PSS}) are summarized in table 6. These spectral changes are completely reversible upon irradiation with narrow-band blue light (interference filter 400 nm / edge filter > 295 nm) suggesting a reversible *E/Z*-isomerisation (**Scheme 6**).

Scheme 6. *E/Z*-Isomerization of *exo-1*.

To prove this assumption we examined the example *exo-1at* in more detail. For this purpose we investigated the irradiation by NMR spectroscopy in CD_2Cl_2 ($c = 5.3 \text{ mM}$, $\lambda_{\text{IRR}} = 300 \text{ nm}$). After several hours the photostationary state is reached with 65% of *E*- and 35% of *Z*-isomer. Irradiation of the same sample with blue light ($\lambda_{\text{IRR}} = 400 \text{ nm}$) caused nearly complete reverse reaction (*E/Z*-ratio = 95 : 5). It should be noted that the *E*- and *Z*-isomers of *exo-1at* could also be separated by HPLC confirming the ratio determined by NMR (see supporting information for details). Furthermore, we found that the thermal reverse reaction is very slow at ambient temperature. In summary, compounds *exo-1* undergo a reversible photochemical *E/Z*-isomerization. However, the *E* \rightarrow *Z*-isomerisation is not complete. Nevertheless, these findings are promising and efficient photoswitches could be accessible by structural variation, e. g. by introducing bulky substituents on the aromatic rings.

Conclusions

In summary, we found that itaconimides undergo rapid Pd-catalyzed Heck-type arylation reactions with arene diazonium salts to furnish arylmethylidene succinimides with high *E*-selectivity. In a comparative investigation we could demonstrate that diazonium salts are indeed much more reactive than the analogous aryl iodides or triflates, and that a second arylation can be achieved only with diazonium salts. Interestingly, the two arylation reactions proceed with different regioselectivities, which we attribute to diverging *exo*- and *endo-β*-hydride elimination pathways. We could demonstrate that the C-C double bond in *exo*-arylmethylidene

1
2
3 succinimides *exo-1* is in principle photoswitchable, but that the *E/Z*-isomerization remains
4
5 incomplete.
6
7
8
9

10 Experimental Section

11
12 **General methods.** All experiments were conducted in dry reaction vessels under an atmosphere
13
14 of dry nitrogen. Solvents were purified by standard procedures. ¹H NMR spectra were obtained
15
16 at 300 MHz, 400 MHz, 500 MHz or 600 MHz in CDCl₃ with CHCl₃ ($\delta = 7.26$ ppm) as an
17
18 internal standard. Coupling constants are given in Hz. ¹³C NMR spectra were recorded at 75
19
20 MHz, 101 MHz, 125 MHz or 150 MHz in CDCl₃ with CDCl₃ ($\delta = 77.1$ ppm) as an internal
21
22 standard. Whenever the solubility or stability of the sample or signal separation were
23
24 insufficient in CDCl₃, it was replaced by one of the following solvents: acetone-*d*₆ (acetone-*d*₅
25
26 as internal standard for ¹H NMR spectroscopy, $\delta = 2.05$ ppm, CD₃COCD₃ as internal standard
27
28 for ¹³C NMR spectroscopy, $\delta = 29.8$ ppm); DMSO-*d*₆ (DMSO-*d*₅ as internal standard for ¹H
29
30 NMR spectroscopy, $\delta = 2.50$ ppm, DMSO-*d*₆ as internal standard for ¹³C NMR spectroscopy,
31
32 $\delta = 39.5$ ppm). ¹⁹F NMR spectra were recorded at 376 MHz with trifluoroacetic acid (0.1 M in
33
34 DMSO-*d*₆) as external standard. In all cases where signal assignments are given for ¹H- and
35
36 ¹³C-NMR data, these are based on 2D-NMR-spectra such as H,H-COSY, HSQC, HMBC and
37
38 NOESY. IR spectra were recorded as ATR-FTIR spectra. Wavenumbers (ν) are given in cm⁻¹.
39
40 The peak intensities are defined as strong (s), medium (m) or weak (w). Low- and high
41
42 resolution mass spectra were obtained by EI-TOF or ESI-TOF. 4-Methoxyphenyltriflate (**8b**)
43
44 was synthesized following a literature procedure⁷⁹ and its analytical data match those previously
45
46 described.⁸⁰ These arene diazonium salts were synthesized following previously published
47
48 procedures: **6a-b**,⁸¹ **6c**,⁴⁶ **6d**,⁸² **6e**,⁸³ **6f**,⁸⁴ **6g**,⁸³ **6h**,⁸⁵ **6i**,⁸⁶ **6j**,⁸⁴ **6k-l**,⁸⁷ **6m-n**,⁸⁸ **6o**,⁸⁵ **6p-q**,⁸⁸ **6r-**
49
50 **6s**,⁴⁶ **6t**,⁸⁹ **6u**.⁸⁸ Diazonium salt **6v** has been mentioned in the literature,⁹⁰ but no synthetic
51
52 procedure and characterization data were provided.
53
54
55
56
57
58
59
60

1
2
3 ***N*-Phenylitaconimide (5a)**. Synthesized by analogy to a literature procedure:⁹ Maleimide **3a**
4 (8.6 g, 50 mmol) was dissolved in glacial acetic acid (40 mL) and PPh₃ (13.1 g, 50 mmol) and
5 paraformaldehyde (7.5 g, 250 mmol) were added. The reaction mixture was heated to reflux for
6 one hour. After cooling to ambient temperature, water (100 mL) was added and the aqueous
7 phase was extracted three times with ethyl acetate (100 mL each). The combined organic phases
8 were washed with brine (100 mL) and dried over MgSO₄ and concentrated under reduced
9 pressure. The crude product was purified by column chromatography on silica, using
10 hexanes/ethyl acetate mixtures of increasing polarity as eluent, to furnish **5a** (5.2 g, 28 mmol,
11 56%): colourless solid, mp 117 - 120 °C (reported in the literature:⁹¹ mp 118 – 120 °C); ¹H
12 NMR (400 MHz, CDCl₃) δ 7.49 (dd, *J* = 7.4, 7.4 Hz, 2H), 7.46 - 7.40 (m, 1H), 7.34 (d, *J* = 7.8
13 Hz, 2H), 6.47 (d, *J* = 1.7 Hz, 1H), 5.74 (d, *J* = 1.5 Hz, 1H), 3.54 - 3.51 (s, 2H); ¹³C{¹H} NMR
14 (101 MHz, CDCl₃) δ 172.9, 168.6, 133.1, 132.0, 129.3, 128.8, 126.5, 121.9, 34.1; IR (ATR) ν
15 1702 (s), 1662 (m), 1496 (m), 1385 (s), 1142 (s); HRMS (EI) calcd for C₁₁H₉NO₂ [M⁺]
16 187.0633, found 187.0626.

17
18
19 ***N*-(3-Hydroxyphenyl)maleimide (3b)**. Synthesized by analogy to a literature procedure:⁹²
20 Maleic anhydride (**8**) (392 mg, 4.0 mmol) and 3-aminophenol (**9**) (470 mg, 4.3 mmol) were
21 dissolved in glacial acetic acid (25 mL) and stirred at reflux temperature until the reaction was
22 completed (ca. 5 h). After cooling to ambient temperature water (50 mL) and ethyl acetate (100
23 mL) were added to the reaction mixture and the layers were separated. The organic phase was
24 washed with saturated sodium bicarbonate solution (3 times 30 mL), dried with MgSO₄ and
25 concentrated under reduced pressure. The crude product was purified by column
26 chromatography on silica, using hexanes/ethyl acetate mixtures of increasing polarity as eluent
27 to furnish **3b** (688 mg, 3.6 mmol, 91%): yellowish solid, mp 135 °C (reported in the literature:⁴²
28 mp 134 – 135 °C); ¹H NMR (300 MHz, acetone-*d*₆) δ 8.58 (s, 1H), 7.32 – 7.16 (m, 1H), 7.02 –
29 6.94 (s, 2H), 6.90 – 6.74 (m, 3H); ¹³C{¹H} NMR (75 MHz, acetone-*d*₆) δ 170.4, 158.5, 135.2,
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 134.0, 130.3, 118.4, 115.5, 114.5; IR (ATR) ν 3321 (w), 1693 (s), 1598 (m), 1150 (m), 825 (s);
4
5 HRMS (EI) calcd for C₁₀H₇NO₃ [M⁺] 189.0426, found 189.0422.
6

7
8 ***N*-(3-Hydroxyphenyl)itaconimide (5b)**. Following the procedure for **5a**, maleimide **3b** (567
9 mg, 3.0 mmol) was converted to **5b** (438 mg, 2.2 mmol, 72%): colourless solid, mp: 168 - 169
10 °C (reported in the literature:⁹³ mp 111 – 112 °C); ¹H NMR (300 MHz, acetone-*d*₆) δ 8.57 (s,
11 1H), 7.28 (ddd, *J* = 8.9, 4.8, 1.4 Hz, 1H), 6.93 –6.78 (m, 3H), 6.26 (td, *J* = 2.5, 0.4 Hz, 1H),
12 5.73 (td, *J* = 2.1, 0.4 Hz, 1H), 3.52 (t, *J* = 2.3 Hz, 2H); ¹³C{¹H} NMR (75 MHz, acetone-*d*₆) δ
13 173.5, 169.2, 158.5, 135.8, 134.9, 130.2, 120.0, 118.9, 116.0, 115.0, 34.6; IR (ATR) ν 3285
14 (bw), 1694 (s), 1665 (m), 1226 (s), 1139 (s); HRMS (EI) calcd for C₁₁H₁₀NO₃ [M+H]⁺
15 204.0661, found 204.0672.
16
17
18
19
20
21
22
23
24
25

26
27 **2,4-Dichlorophenyldiazoniumtetrafluoroborate (6v)**. A solution of 2,4-dichloroaniline (972
28 mg, 6.00 mmol) in aq. HBF₄ (48 wt-%, 2.00 mL, 7.80 mmol) and water (2.00 mL) was cooled
29 to 0 °C. A solution of NaNO₂ (414 mg, 6.00 mmol) in water (1.00 mL) was added dropwise
30 and the reaction mixture was stirred for 0.5 h at 0 °C. The resulting precipitate was filtered off,
31 dissolved in acetone (3 mL) and re-precipitated by addition of diethyl ether (150 mL). Filtration
32 and drying in vacuo furnished **6v** (66 %, 1.030 g, 4.00 mmol): colourless solid; ¹H NMR (400
33 MHz, DMSO-*d*₆) δ 8.86 (d, *J* = 9.0 Hz, 1H), 8.54 (d, *J* = 1.5 Hz, 1H), 8.10 (dd, *J* = 8.9, 1.5 Hz,
34 1H); ¹³C{¹H} NMR (101 MHz, DMSO-*d*₆) δ 147.6, 136.8, 135.5, 132.4, 130.7, 115.5; IR (ATR)
35 ν 3095 (m), 2287 (w), 1739 (s), 1367 (m), 1055 (s); HRMS (ESI) calcd for C₆H₃³⁵Cl₂N₂ [M]⁺
36 172.9668, found: 172.9669.
37
38
39
40
41
42
43
44
45
46
47
48

49 **General procedure for the Matsuda-Heck reaction of *N*-arylitaconimides with arene**
50 **diazonium salts**. The appropriate *N*-arylitaconimide **5a** (56 mg, 0.30 mmol) or **5b** (61 mg, 0.30
51 mmol) was dissolved in methanol (4.0 mL). Pd(OAc)₂ (2.8 mg, 5 mol %) and the corresponding
52 arene diazonium tetrafluoroborate **6** (0.25 mmol) were added and the mixture was stirred at
53 ambient temperature for 0.5 h. The products precipitate from the mixture and were isolated by
54 filtration of the reaction mixture through a short pad of celite, which was subsequently washed
55
56
57
58
59
60

with methanol (10 mL) to remove unreacted starting material **5**. The pad of celite is then flushed with ethyl acetate (10 mL) to dissolve the product. Evaporation of the ethyl acetate solution furnished the products *exo-1* without additional purification steps.

(E)-3-(4-Methoxybenzylidene)-1-phenylpyrrolidine-2,5-dione (exo-1aa). Following the general procedure, **6a** (56 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were converted to *exo-1aa* (70 mg, 0.24 mmol, 95%): off-white solid, mp 149 – 151 °C (reported in the literature:²¹ mp 175 – 177 °C); ¹H NMR (300 MHz, CDCl₃) δ 7.68 (t, *J* = 2.2 Hz, 1H), 7.52 – 7.45 (m, 4H), 7.43 – 7.32 (m, 3H), 6.99 (d, *J* = 8.8 Hz, 2H), 3.86 (s, 3H), 3.70 (d, *J* = 2.3 Hz, 2H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 173.3, 170.4, 161.4, 135.1, 132.3, 132.3, 129.2, 128.5, 127.0, 126.6, 120.4, 114.8, 55.6, 34.4; IR (ATR) ν 2923 (m), 1764 (m), 1699 (s), 1597 (m), 1373 (m); HRMS (EI) calcd for C₁₈H₁₅NO₃ [M⁺] 293.1052, found 293.1048.

(E)-3-(4-(Benzyloxy)benzylidene)-1-phenylpyrrolidine-2,5-dione (exo-1ab). Following the general procedure, **6b** (75 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were converted to *exo-1ab* (75 mg, 0.20 mmol, 81%): colourless solid, mp 190 - 191 °C; ¹H NMR (600 MHz, DMSO-*d*₆) δ 7.67 (d, *J* = 8.9 Hz, 2H), 7.55 - 7.49 (m, 3H), 7.49 - 7.46 (m, 2H), 7.45 - 7.39 (m, 3H), 7.37 - 7.32 (m, 3H), 7.14 (dm, *J* = 8.9 Hz, 2H), 5.20 (s, 2H), 3.82 (d, *J* = 2.3 Hz, 2H); ¹³C{¹H} NMR (151 MHz, DMSO-*d*₆) δ 173.6, 170.2, 159.7, 136.7, 132.7, 132.6, 132.3, 128.8, 128.5, 128.2, 128.0, 127.8, 127.2, 127.0, 122.4, 115.4, 69.4, 34.1; IR (ATR) ν 1772 (w), 1702 (s), 1598 (m), 1170 (s), 827 (m); HRMS (ESI) calcd for C₂₄H₂₀NO₃ [M+H]⁺ 370.1443, found 370.1435.

(E)-3-(4-Hydroxybenzylidene)-1-phenylpyrrolidine-2,5-dione (exo-1ac). Following the general procedure, **6c** (52 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were converted to *exo-1ac* (64 mg, 0.23 mmol, 92%): off-white solid, mp 270 °C (dec.); ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.13 (s, 1H), 7.55 (d, *J* = 8.7 Hz, 2H), 7.53 - 7.49 (m, 2H), 7.48 (t, *J* = 2.2 Hz, 1H), 7.42 (tt, *J* = 7.7, 1.3 Hz, 1H), 7.36 - 7.33 (m, 2H), 6.88 (dm, *J* = 8.7 Hz, 2H), 3.78 (d, *J* = 2.3 Hz, 2H); ¹³C{¹H} NMR (151 MHz, DMSO-*d*₆) δ 173.6, 170.3, 159.4, 133.1, 132.8, 132.6, 128.8,

1
2
3 128.2, 127.2, 125.3, 121.1, 116.0, 34.1; IR (ATR) ν 3393 (w), 1769 (m), 1689 (s), 1596 (s),
4
5 1385 (s), 1158 (s); HRMS (ESI) calcd for $C_{17}H_{14}NO_3$ $[M+H]^+$ 280.0974, found 280.0971.

7 **(E)-3-(4-Fluorobenzylidene)-1-phenylpyrrolidine-2,5-dione (exo-1ad)**. Following the
8
9 general procedure, **6d** (52 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were converted to *exo*-
10
11 **1ad** (64 mg, 0.23 mmol, 91%): off-white solid, mp 194 - 197 °C (reported in the literature:²¹
12
13 mp 232 – 233 °C); 1H NMR (400 MHz, $CDCl_3$) δ 7.71 (s, 1H), 7.57 - 7.48 (m, 4H), 7.45 - 7.36
14
15 (m, 3H), 7.18 (dd, $J = 8.2, 8.2$ Hz, 2H), 3.73 (s, 2H); $^{13}C\{^1H\}$ NMR (101 MHz, $CDCl_3$) δ 172.9,
16
17 170.0, 163.7 (d, $J = 253.2$ Hz), 134.1, 132.3 (d, $J = 8.6$ Hz), 132.0, 130.4 (d, $J = 3.3$ Hz), 129.2,
18
19 128.7, 126.5, 122.7 (d, $J = 2.3$ Hz), 16.5 (d, $J = 21.9$ Hz), 34.1; $^{19}F\{^1H\}$ NMR (376 MHz,
20
21 $CDCl_3$) δ -108.3; IR (ATR) ν 1762 (w), 1702 (s), 1650 (m), 1598 (m), 1173 (s), 1160 (s);
22
23 HRMS (ESI) calcd for $C_{17}H_{13}FNO_2$ $[M+H]^+$ 282.0900, found 282.0930.

24
25
26
27 **(E)-3-(4-Chlorobenzylidene)-1-phenylpyrrolidine-2,5-dione (exo-1ae)**. Following the
28
29 general procedure, **6e** (57 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were converted to *exo*-
30
31 **1ae** (67 mg, 0.23 mmol, 91%): colourless solid, mp 232 - 233 °C (reported in the literature:⁵
32
33 mp 233 – 235 °C); 1H NMR (500 MHz, $DMSO-d_6$) δ 7.74 (d, $J = 8.6$ Hz, 2H), 7.60 - 7.50 (m,
34
35 5H), 7.44 (t, $J = 7.4$ Hz, 1H), 7.38 - 7.33 (m, 2H), 3.86 (d, $J = 2.3$ Hz, 2H); $^{13}C\{^1H\}$ NMR (125
36
37 MHz, $DMSO-d_6$) δ 173.4, 169.8, 134.5, 133.1, 132.6, 132.0, 131.3, 129.1, 128.9, 128.3, 127.1,
38
39 126.2, 34.1; IR (ATR) ν 1762 (w), 1701 (s), 1499 (m), 1173 (s), 825 (m); HRMS (ESI) calcd
40
41 for $C_{17}H_{13}^{35}ClNO_2$ $[M+H]^+$ 298.0635, found 298.0645.

42
43
44
45
46
47 **(E)-3-(4-Bromobenzylidene)-1-phenylpyrrolidine-2,5-dione (exo-1af)**. Following the
48
49 general procedure, **6f** (68 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were converted to *exo*-
50
51 **1af** (79 mg, 0.23 mmol, 93%): off-white solid, mp 234 – 235 °C (reported in the literature:²¹
52
53 mp 235 – 236 °C); 1H NMR (600 MHz, $DMSO-d_6$) δ 7.74 – 7.62 (m, 4H), 7.56 (t, $J = 1.7$ Hz,
54
55 1H), 7.52 (dd, $J = 7.7, 7.7$ Hz, 2H), 7.44 (t, $J = 7.4$ Hz, 1H), 7.36 (d, $J = 7.6$ Hz, 2H), 3.84 (d,
56
57 $J = 1.6$ Hz, 2H); $^{13}C\{^1H\}$ NMR (151 MHz, $DMSO-d_6$) δ 173.4, 169.8, 133.4, 132.6, 132.2,
58
59
60

1
2
3 132.0, 131.4, 128.9, 128.3, 127.1, 126.3, 123.5, 34.1; IR (ATR) ν 1763 (m), 1702 (s), 1638 (m),
4
5 1485 (m), 1172 (s); HRMS (ESI) calcd for C₁₇H₁₃⁷⁹BrNO₂ [M+H]⁺ 342.0130, found 342.0129.

7 **(E)-3-(4-Cyanobenzylidene)-1-phenylpyrrolidine-2,5-dione (exo-1ag)**. Following the
8
9 general procedure, **6g** (54 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were converted to *exo*-
10
11 **1ag** (62 mg, 0.22 mmol, 86%): off-white solid, mp 233 °C (dec.); ¹H NMR (600 MHz, DMSO-
12
13 *d*₆) δ 7.96 (dm, *J* = 8.5 Hz, 2H), 7.90 (dm, *J* = 8.4 Hz, 2H), 7.64 (t, *J* = 2.4 Hz, 1H), 7.55 - 7.50
14
15 (m, 2H), 7.45 (tt, *J* = 7.5, 1.3 Hz, 1H), 7.38 - 7.34 (m, 2H), 3.91 (d, *J* = 2.4 Hz, 2H); ¹³C {¹H}
16
17 NMR (151 MHz, DMSO-*d*₆) δ 173.3, 169.6, 138.7, 132.8, 132.5, 130.8, 130.6, 129.0, 128.9,
18
19 128.4, 127.1, 118.6, 111.8, 34.2; IR (ATR) ν 2232 (w), 1764 (w), 1703 (s), 1645 (w), 1172 (m),
20
21 689 (s); HRMS (ESI) calcd. for C₁₈H₁₃N₂O₂ [M+H]⁺ 289.0977, found 289.0984.

22
23
24 **(E)-3-(4-Acetylbenzylidene)-1-phenylpyrrolidine-2,5-dione (exo-1ah)**. Following the
25
26 general procedure, **6h** (56 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were converted to *exo*-
27
28 **1ah** (72 mg, 0.24 mmol, 94%): off-white solid, mp 177 - 181 °C (dec.); ¹H NMR (600 MHz,
29
30 DMSO-*d*₆) δ 8.04 (d, *J* = 8.4 Hz, 2H), 7.85 (d, *J* = 8.4 Hz, 2H), 7.64 (t, *J* = 2.2 Hz, 1H), 7.57 -
31
32 7.49 (m, 2H), 7.44 (dd, *J* = 7.3, 1.4 Hz, 1H), 7.39 - 7.31 (m, 2H), 3.91 (d, *J* = 2.4 Hz, 2H), 2.62
33
34 (s, 3H); ¹³C {¹H} NMR (151 MHz, DMSO-*d*₆) δ 197.5, 173.4, 169.8, 138.4, 137.0, 132.6, 131.3,
35
36 130.5, 128.9, 128.7, 128.4, 128.0, 127.2, 34.3, 26.9; IR (ATR) ν 1765 (w), 1703 (s), 1677 (s),
37
38 1643 (m), 1348 (m), 1175 (s); HRMS (ESI) calcd for C₁₉H₁₆NO₃ [M+H]⁺ 306.1130, found
39
40 306.1115.

41
42
43 **(E)-N-(4-((2,5-Dioxo-1-phenylpyrrolidine-3-ylidene)methyl)phenyl)acetamide (exo-1ai)**.
44
45 Following the general procedure, **6i** (62 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were
46
47 converted to *exo*-**1ai** (72 mg, 0.23 mmol, 90%): colourless solid, mp 260 - 265 °C (dec.); ¹H
48
49 NMR (600 MHz, DMSO-*d*₆) δ 10.19 (s, 1H), 7.68 (d, *J* = 8.7 Hz, 2H), 7.62 (d, *J* = 8.8 Hz, 2H),
50
51 7.48 (dd, *J* = 7.5, 7.5 Hz, 2H), 7.47 (t, *J* = 2.2 Hz, 1H), 7.40 (tt, *J* = 7.5, 1.3 Hz, 1H), 7.32 (dm,
52
53 *J* = 7.5 Hz, 1H), 3.80 (d, *J* = 2.2 Hz, 2H), 2.05 (s, 3H); ¹³C {¹H} NMR (151 MHz, DMSO-*d*₆) δ
54
55 173.6, 170.1, 168.8, 140.9, 132.7, 132.5, 131.4, 128.9, 128.8, 128.2, 127.2, 123.2, 119.0, 34.2,
56
57
58
59
60

24.1; IR (ATR): 3324 (w), 1760 (w), 1697 (s), 1649 (m), 1177 (s); HRMS (ESI) calcd for $C_{19}H_{17}N_2O_3$ $[M+H]^+$ 321.1239, found 321.1260.

(E)-3-(4-Nitrobenzylidene)-1-phenylpyrrolidine-2,5-dione (exo-1aj). Following the general procedure, **6j** (59 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were converted to *exo-1aj* (69 mg, 0.22 mmol, 89%): yellow solid, mp 227 - 229 °C (dec.; reported in the literature for an *E/Z*-mixture:²² mp 140 - 142 °C); 1H NMR (600 MHz, DMSO- d_6) δ 8.31 (dm, J = 8.8 Hz, 2H), 7.99 (dm, J = 8.9 Hz, 2H), 7.70 (t, J = 2.4 Hz, 1H), 7.53 (dd, J = 7.9, 7.5 Hz, 2H), 7.45 (tt, J = 7.6, 1.2 Hz, 1H), 7.37 (dd, J = 8.0, 1.2 Hz, 2H), 3.93 (d, J = 2.4 Hz, 2H); ^{13}C $\{^1H\}$ NMR (151 MHz, DMSO- d_6) δ 173.2, 169.6, 147.4, 140.5, 132.5, 131.3, 130.0, 129.8, 128.9, 128.4, 127.1, 124.0, 34.2; IR (ATR) ν 1764 (w), 1701 (s), 1647 (m), 1515 (s), 1347 (s); HRMS (ESI) calcd for $C_{17}H_{12}N_2O_4$ $[M^+]$ 308.0792, found 308.0790.

(E)-3-Benzylidene-1-phenylpyrrolidine-2,5-dione (exo-1ak). Following the general procedure, **6k** (48 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were converted to *exo-1ak* (59 mg, 0.22 mmol, 88%): colourless solid, mp 191 - 193 °C (reported in the literature:⁷ mp 189 - 190 °C); 1H NMR (300 MHz, DMSO- d_6) δ 7.70 (dd, J = 8.0, 1.2 Hz, 2H), 7.58 (t, J = 2.2 Hz, 1H), 7.56 - 7.46 (m, 5H), 7.44 (tt, J = 7.5, 1.4 Hz, 1H), 7.37 (dd, J = 8.0, 1.4 Hz, 2H), 3.87 (d, J = 2.3 Hz, 2H); ^{13}C $\{^1H\}$ NMR (75 MHz, DMSO- d_6) δ 173.4, 169.9, 134.1, 132.7, 132.6, 130.3, 129.9, 129.0, 128.8, 128.2, 127.1, 125.3, 34.1; IR (ATR) ν 1775 (w), 1703 (s), 1657 (m), 1388 (m), 1123 (m); HRMS (ESI) calcd for $C_{17}H_{13}NO_2$ $[M^+]$ 263.0946, found 263.0945.

(E)-3-(3-Methylbenzylidene)-1-phenylpyrrolidine-2,5-dione (exo-1al). Following the general procedure, **6l** (52 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were converted to *exo-1al* (69 mg, 0.25 mmol, quant.): colourless solid, mp 172 °C; 1H NMR (600 MHz, DMSO- d_6) δ 7.55 - 7.48 (m, 5H), 7.44 (tt, J = 7.5, 1.3 Hz, 1H), 7.39 (dd, J = 7.6, 7.6 Hz, 1H), 7.36 (dd, J = 8.0, 1.3 Hz, 2H), 7.28 (d, J = 7.6 Hz, 1H), 3.86 (d, J = 2.3 Hz, 2H), 2.38 (s, 3H); ^{13}C $\{^1H\}$ NMR (151 MHz, DMSO- d_6) δ 173.5, 170.0, 138.4, 134.1, 132.8, 132.6, 130.8, 130.7, 129.0,

1
2
3 128.8, 128.3, 127.6, 127.2, 125.1, 34.2, 21.0; IR (ATR) ν 1765 (w), 1702 (s), 1651 (m), 1160
4 (m), 695 (s); HRMS (ESI) calcd for $C_{18}H_{16}NO_2$ $[M+H]^+$ 278.1181, found 278.1161.

7
8 **(E)-3-(3-Cyanobenzylidene)-1-phenylpyrrolidine-2,5-dione (exo-1am)**. Following the
9 general procedure, **6m** (54 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were converted to *exo*-
10 **1am** (64 mg, 0.22 mmol, 89%): yellowish solid, mp 213 - 216 °C; 1H NMR (300 MHz, DMSO-
11 d_6) δ 8.18 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.91 (ddd, J = 7.9, 1.1, 1.1 Hz, 1H), 7.70 (dd, J =
12 7.9, 7.9 Hz, 1H), 7.61 (t, J = 2.3 Hz, 1H), 7.56 - 7.49 (m, 2H), 7.47 - 7.41 (m, 1H), 7.39 - 7.34
13 (m, 2H), 3.95 (d, J = 2.4 Hz, 2H); $^{13}C\{^1H\}$ NMR (75 MHz, DMSO- d_6) δ 173.3, 169.6, 135.3,
14 134.5, 133.5, 133.0, 132.5, 130.3, 130.2, 128.8, 128.3, 127.9, 127.1, 118.4, 112.3, 33.9; IR
15 (ATR) ν 2230 (w), 1760 (w), 1700 (s), 1643 (m), 1380 (m), 1182 (s); HRMS (ESI) calcd for
16 $C_{18}H_{13}N_2O_2$ $[M+H]^+$ 289.0977, found 289.0993.

17
18
19
20
21
22
23
24
25
26
27
28 **(E)-3-(2-Methoxybenzylidene)-1-phenylpyrrolidine-2,5-dione (exo-1an)**. Following the
29 general procedure, **6n** (56 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were converted to *exo*-
30 **1an** (64 mg, 0.22 mmol, 87%): off-white solid, mp 163 - 165 °C (reported in the literature:⁹⁴
31 mp 159 - 160 °C); 1H NMR (600 MHz, DMSO- d_6) δ 7.87 (t, J = 1.8 Hz, 1H), 7.63 (dd, J = 7.8,
32 0.9 Hz, 1H), 7.54 - 7.50 (m, 2H), 7.48 - 7.42 (m, 2H), 7.35 (d, J = 7.3 Hz, 2H), 7.14 (d, J = 8.3
33 Hz, 1H), 7.07 (dd, J = 7.5, 7.5 Hz, 1H), 3.89 (s, 3H), 3.80 (d, J = 2.2 Hz, 2H); $^{13}C\{^1H\}$ NMR
34 (151 MHz, DMSO- d_6) δ 174.0, 170.5, 158.6, 133.1, 132.2, 129.7, 129.3, 128.7, 127.6, 127.3,
35 125.3, 122.9, 121.2, 112.1, 56.2, 34.4; IR (ATR) ν 1758 (w), 1703 (s), 1598 (w), 1382 (w), 696
36 (s); HRMS (ESI) calcd for $C_{18}H_{16}NO_3$ $[M+H]^+$ 294.1130, found 294.1123.

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 **(E)-3-(2-Fluorobenzylidene)-1-phenylpyrrolidine-2,5-dione (exo-1ao)**. Following the
general procedure, **6o** (52 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were converted to *exo*-
1ao (69 mg, 0.25 mmol, 99%): colourless solid, mp 159 - 161 °C (dec.); 1H NMR (500 MHz,
DMSO- d_6) δ 7.79 (t, J = 7.6 Hz, 1H), 7.65 (t, J = 2.0 Hz, 1H), 7.57 - 7.50 (m, 3H), 7.45 (t, J =
7.5 Hz, 1H), 7.40 - 7.27 (m, 4H), 3.85 (d, J = 2.0 Hz, 2H); $^{13}C\{^1H\}$ NMR (126 MHz, DMSO-
 d_6) δ 173.3, 169.6, 160.7 (d, J = 250.5 Hz), 132.5, 132.2 (d, J = 9.0 Hz), 129.9, 128.9, 128.3,

1
2
3 127.8, 127.2, 125.1 (d, $J = 3.5$ Hz), 123.4 (d, $J = 6.3$ Hz), 121.8 (d, $J = 11.5$ Hz), 116.0 (d, $J =$
4 21.7 Hz), 34.0; IR (ATR) ν 1774 (w), 1703 (s), 1498 (m), 1198 (m), 697 (s); HRMS (ESI) calcd
5 for $C_{17}H_{13}FNO_2$ $[M+H]^+$ 282.0930, found 282.0902.
6
7


8
9
10 **(E)-3-(2-Bromobenzylidene)-1-phenylpyrrolidine-2,5-dione (exo-1ap)**. Following the
11 general procedure, **6p** (68 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were converted to *exo-*
12 **1ap** (61 mg, 0.18 mmol, 72%): colourless solid, mp 155 - 157 °C (dec.); 1H NMR (600 MHz,
13 DMSO- d_6) δ 7.80 (dd, $J = 7.8, 1.5$ Hz, 1H), 7.79 (dd, $J = 7.9, 1.1$ Hz, 1H), 7.76 (t, $J = 2.4$ Hz,
14 1H), 7.56 – 7.50 (m, 3H), 7.45 (tt, $J = 7.3, 1.3$ Hz, 1H), 7.40 (ddd, $J = 7.9, 7.9, 1.6$ Hz, 1H),
15 7.38 – 7.36 (m, 2H), 3.84 (d, $J = 2.4$ Hz, 2H); $^{13}C\{^1H\}$ NMR (151 MHz, DMSO- d_6) δ 173.3,
16 169.6, 133.4, 133.3, 132.5, 131.5, 130.3, 130.2, 128.9, 128.4, 128.4, 128.3, 127.2, 125.4, 33.5;
17 IR (ATR) ν 1761 (w), 1705 (s), 1500 (m), 1384 (m), 1171 (m); HRMS (ESI) calcd for
18 $C_{17}H_{13}^{79}BrNO_2$ $[M+H]^+$ 342.0130, found 342.0140.
19
20
21
22
23
24
25
26
27
28
29

30
31 **(E)- 3-(3-Bromo-4-hydroxybenzylidene)-1-phenylpyrrolidine-2,5-dione (exo-1ar)**.
32 Following the general procedure, **6r** (72 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were
33 converted to *exo-1ar* (85 mg, 0.24 mmol, 95%): off-white solid, mp 185 °C (dec.); 1H NMR
34 (600 MHz, DMSO- d_6) δ 10.97 (s, 1H), 7.85 (s, 1H), 7.57 (d, $J = 8.4$ Hz, 1H), 7.51 (dd, $J = 7.7,$
35 7.7 Hz, 2H), 7.47 (s, 1H), 7.43 (t, $J = 7.4$ Hz, 1H), 7.35 (d, $J = 7.6$ Hz, 2H), 7.06 (d, $J = 8.5$ Hz,
36 1H), 3.82 (s, 2H); $^{13}C\{^1H\}$ NMR (151 MHz, DMSO- d_6) δ 173.5, 170.0, 155.8, 135.4, 132.7,
37 131.6, 131.0, 128.8, 128.2, 127.2, 126.9, 122.8, 116.7, 110.0, 34.0; IR (ATR) ν 3405 (w), 1770
38 (m), 1691 (s), 1505 (m), 1169 (s); HRMS (ESI) calcd for $C_{17}H_{13}^{79}BrNO_3$ $[M+H]^+$ 358.0079,
39 found 358.0108.
40
41
42
43
44
45
46
47
48
49
50

51
52 **Methyl (E)-5-((2,5-dioxo-1-phenylpyrrolidin-3-ylidene)methyl)-2-hydroxybenzoate (exo-**
53 **1as)**. Following the general procedure, **6s** (67 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were
54 converted to *exo-1as* (78 mg, 0.23 mmol, 93%): off-white solid, mp 195 °C; 1H NMR (600
55 MHz, DMSO- d_6) δ 10.85 (s, 1H), 8.07 (d, $J = 2.3$ Hz, 1H), 7.86 (dd, $J = 8.8, 2.3$ Hz, 1H), 7.55
56 (t, $J = 2.3$ Hz, 1H), 7.54 - 7.50 (m, 2H), 7.43 (tt, $J = 7.5, 1.3$ Hz, 1H), 7.37 - 7.34 (m, 2H), 7.11
57
58
59
60

(d, $J = 8.7$ Hz, 1H), 3.92 (s, 3H), 3.82 (d, $J = 2.3$ Hz, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, DMSO- d_6) δ 173.4, 170.0, 168.2, 160.6, 136.7, 132.9, 132.6, 131.7, 128.8, 128.2, 127.1, 125.7, 123.4, 118.4, 114.6, 52.7, 34.0; IR (ATR) ν 1703 (s), 1682 (s), 1591 (m), 1216 (m), 698 (s); HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{16}\text{NO}_5$ $[\text{M}+\text{H}]^+$ 338.1028, found 338.1046.

(E)-1-Phenyl-3-(3,4,5-trimethoxybenzylidene)pyrrolidine-2,5-dione (exo-1at).



Following the general procedure, **6t** (71 mg, 0.25 mmol) and **5a** (56 mg, 0.30 mmol) were converted to *exo*-**1at** (79 mg, 0.23 mmol, 90%): colourless solid, mp 172 - 173 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.65 (t, $J = 2.3$ Hz, 1H, H⁶), 7.50 (tm, $J = 7.7$ Hz, 2H, H^{11,13}), 7.44 – 7.35 (m, 3H, H^{10,12,14}), 6.75 (s, 2H, H^{16,20}), 3.92 (s, 3H, H²¹), 3.90 (s, 6H, H^{22,23}), 3.78 (d, $J = 2.3$ Hz, 2H, H²); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 173.2 (C³), 170.1 (C⁵), 153.7 (C^{17,19}), 140.4 (C¹⁸), 135.6 (C⁶), 132.1 (C⁹), 129.6 (C¹⁵), 129.3 (C^{11,13}), 128.7 (C¹²), 126.6 (C^{10,14}), 122.0 (C¹), 107.8 (C^{16,20}), 61.1 (C²¹), 56.4 (C^{22,23}), 34.4 (C²); IR (ATR) ν 1772 (m), 1700 (s), 1652 (m), 1575 (m), 1115 (s); HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{20}\text{NO}_5$ $[\text{M}+\text{H}]^+$ 354.1341, found 354.1343.

(E)-1-(3-Hydroxyphenyl)-3-(3-nitrobenzylidene)pyrrolidine-2,5-dione (exo-1bu).

Following the general procedure, **6u** (119 mg, 0.50 mmol) and **5b** (122 mg, 0.60 mmol) were converted to *exo*-**1bu** (128 mg, 0.40 mmol, 79%): yellowish solid, mp 212 °C (dec.; reported in the literature:¹ mp 198 - 199 °C); ^1H NMR (300 MHz, DMSO- d_6) δ 9.74 (s, 1H), 8.50 (t, $J = 1.5$ Hz, 1H), 8.27 (ddd, $J = 8.2, 2.2, 0.7$ Hz, 1H), 8.15 (d, $J = 7.9$ Hz, 1H), 7.78 (dd, $J = 7.9, 7.9$ Hz, 1H), 7.71 (t, $J = 2.2$ Hz, 1H), 7.30 (t, $J = 8.3$ Hz, 1H), 6.84 (ddd, $J = 8.2, 2.3, 1.0$ Hz, 1H), 6.80 - 6.75 (m, 2H), 3.92 (d, $J = 2.3$ Hz, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, DMSO- d_6) δ 173.0, 169.4, 157.6, 148.2, 135.8, 135.8, 133.3, 130.5, 130.1, 129.5, 128.3, 124.6, 124.0, 117.5, 115.3, 114.1, 33.9; IR (ATR) ν 3281 (bw), 1770 (m), 1693 (s), 1653 (s), 1526 (s); HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{13}\text{N}_2\text{O}_5$ $[\text{M}+\text{H}]^+$ 325.0824, found 325.0839.

(E)-3-(2,4-Dichlorobenzylidene)-1-(3-hydroxyphenyl)pyrrolidine-2,5-dione (exo-1bv).

Following the general procedure, **6v** (130 mg, 0.50 mmol) and **5b** (122 mg, 0.60 mmol) were converted to *exo*-**1bv** (167 mg, 0.48 mmol, 96%): orange solid, mp 255 °C (dec.; reported in the literature:¹ mp 269 °C); ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.79 (s, 1H), 7.82 (d, *J* = 2.3 Hz, 1H), 7.82 (d, *J* = 8.4 Hz, 1H), 7.71 (t, *J* = 2.4 Hz, 1H), 7.56 (dd, *J* = 8.4, 1.9 Hz, 1H), 7.30 (dd, *J* = 8.3, 8.3 Hz, 1H), 6.84 (ddd, *J* = 8.2, 2.3, 1.0 Hz, 1H), 6.79 - 6.74 (m, 2H), 3.82 (d, *J* = 2.5 Hz, 2H); ¹³C{¹H} NMR (126 MHz, DMSO-*d*₆) δ 173.2, 169.4, 157.7, 135.3, 135.0, 133.3, 131.2, 130.8, 129.6, 129.6, 129.2, 128.1, 126.3, 117.6, 115.4, 114.2, 33.7; IR (ATR) ν 3374 (bw), 1765 (m), 1697 (s), 1387 (m), 1181 (s); HRMS (ESI) calcd for C₁₇H₁₂³⁵Cl₂NO₃ [M+H]⁺ 348.0194, found 348.0185.


Synthesis of (E)-3-(4-methoxybenzylidene)-1-phenylpyrrolidine-2,5-dione (exo-1aa) via

Mizoroki-Heck reaction. *Iodo-4-Methoxybenzene (8a) as coupling partner (table 2, entries 1 and 2):* To a solution of **8a** (70 mg, 0.30 mmol) and **5a** (47 mg, 0.25 mmol) in DMF (2.0 mL) were added NEt₃ (105 μL, 0.75 mmol), Pd(OAc)₂ (2.8 mg, 5 mol%) and tri-(*o*-tolyl)-phosphine (7.6 mg, 10 mol%). The solution was heated to 90 °C in DMF (2.0 mL) at 90 °C for 18 h. After cooling to ambient temperature the reaction mixture was diluted with CH₂Cl₂ (30 mL), washed with water (20 mL) and brine (20 mL). The organic extracts were dried with MgSO₄, filtered and concentrated at reduced pressure. The crude product was purified by column chromatography using silica gel and eluent mixtures of hexanes and ethyl acetate with increasing polarity to furnish *exo*-**1aa** (51 mg, 0.18 mmol, 70%) as an off-white solid. By following this procedure without addition of the ligand tri-(*o*-tolyl)-phosphine the same coupling product *exo*-**1aa** (44 mg, 0.15 mmol, 60%) was obtained. *4-Methoxyphenyltriflate (8b) as coupling partner (table 2, entry 4):* the same procedure as outlined above was used, but **8a** was replaced by **8b** (77 mg, 0.30 mmol). The identical coupling product *exo*-**1aa** (19 mg, 0.07 mmol, 26%) was obtained. *Bromo-4-methoxybenzene (8c) as coupling partner (table 2, entry 5):* Pd(OAc)₂ (2.8 mg, 5 mol%) and tri-(*o*-tolyl)-phosphine (7.6 mg, 10 mol%) were suspended

1
2
3 in DMF (2.00 mL) and the mixture was stirred for 20 minutes at ambient temperature. 4-
4 Bromoanisole (**8c**, 38 μ L, 0.30 mmol) was then added, followed by **5a** (47 mg, 0.25 mmol) and
5
6 NaOAc \cdot 3H₂O (34 mg, 0.25 mmol). The reaction mixture was heated to 140 ° C and stirred at
7
8 this temperature for 1 h. After cooling to ambient temperature, the reaction mixture was diluted
9
10 with CH₂Cl₂ (15 mL) and washed with water (30 mL). The aqueous layer was separated and
11
12 extracted three times with CH₂Cl₂ (15 mL each). The combined organic extracts were dried
13
14 with MgSO₄, filtered and evaporated. The crude product was purified by column
15
16 chromatography on silica gel using hexanes / ethyl acetate mixtures of increasing polarity as
17
18 eluent to furnish *exo*-**1aa** (15 mg, 0.05 mmol, 21%). All analytical data of the coupling product
19
20
21
22
23
24
25 *exo*-**1aa** are identical to those reported above.

26 **General procedure for the Matsuda-Heck reaction of arylmethylidene-N-**
27
28 **phenylsuccinimides with arene diazonium salts.** The appropriate precursor *exo*-**1** (0.25
29
30 mmol) was dissolved in methanol (10.0 mL). Pd(OAc)₂ (2.8 mg, 5 mol %), followed by the
31
32 corresponding arene diazonium salt **6** (0.30 mmol) were added, and the mixture was stirred at
33
34 ambient temperature for 18 h. After evaporation of all volatiles *in vacuo* the residue was purified
35
36 by column chromatography on silica, using hexanes-ethyl acetate mixtures of increasing
37
38 polarity as eluents.
39
40
41

42 **3-(Bis-(4-methoxyphenyl)methyl)-1-phenyl-1H-pyrrol-2,5-dione (*endo*-**7aa**).**



43
44
45
46
47
48
49
50
51
52
53
54 Following the general procedure, *exo*-**1aa** (73 mg, 0.25 mmol) and **6a** (67 mg, 0.30 mmol) were
55
56 converted to *endo*-**7aa** (86 mg, 0.22 mmol, 86%). *Alternative synthesis from 5a (table 1, entry*
57
58 *8).* To a solution of **5a** (47 mg, 0.25 mmol) in methanol (8.0 mL) was added Pd(OAc)₂ (2.8 mg,
59
60 5 mol %) and arene diazonium tetrafluoroborate **6a** (166 mg, 0.75 mmol). The reaction mixture

1
2
3 was stirred at ambient temperature for 18 h, evaporated, and the residue was purified by column
4 chromatography on silica using hexanes-ethyl acetate mixtures of increasing polarity to furnish
5
6
7 *endo-7aa* (32 mg, 0.16 mmol, 65%): colourless oil; ^1H NMR (400 MHz, CDCl_3) δ 7.43 (dd, J
8 = 7.7, 7.7 Hz, 2H, $\text{H}^{13/15}$), 7.35 (d, J = 7.5 Hz, 2H, $\text{H}^{12/16}$), 7.32 (t, J = 7.2 Hz, 1H, H^{14}), 7.13 (d,
9 J = 8.3 Hz, 4H, $\text{H}^{17,21,22,26}$), 6.89 (d, J = 8.3 Hz, 4H, $\text{H}^{18,20,23,25}$), 6.28 (s, 1H, H^2), 5.33 (s, 1H,
10 H^6), 3.80 (s, 6H, $\text{H}^{27,28}$); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 169.6 (C^3), 169.3 (C^5), 158.8
11 ($\text{C}^{19,24}$), 152.5 (C^1), 131.8 ($\text{C}^{7,8}$), 131.6 (C^{11}), 129.5 ($\text{C}^{17,21,22,26}$), 129.0 ($\text{C}^{12,16}$), 128.6 (C^2), 127.6
12 (C^{14}), 125.8 ($\text{C}^{12,16}$), 114.3 ($\text{C}^{18,20,23,25}$), 55.3 ($\text{C}^{27,28}$), 46.4 (C^6); IR (ATR) ν 2925 (w), 1714 (s),
13 1604 (w), 1510 (s), 1388 (m); HRMS (ESI) calcd for $\text{C}_{25}\text{H}_{21}\text{NO}_4$ [M^+] 399.1471, found
14 399.1460.

15
16
17
18
19
20
21
22
23
24
25
26 **3-((4-Chlorophenyl)(4-methoxyphenyl)methyl)-1-phenyl-1*H*-pyrrole-2,5-dione** (*endo-*
27 **7ae**). Following the general procedure, *exo-1aa* (73 mg, 0.25 mmol) and **6e** (68 mg, 0.30 mmol)
28 were converted to *endo-7ae* (84 mg, 0.21 mmol, 83%). *Alternative synthesis from 5a* (scheme
29 4). To a solution of **5a** (56 mg, 0.30 mmol) in methanol (4.0 mL) was added $\text{Pd}(\text{OAc})_2$ (2.8 mg,
30 5 mol %) and arene diazonium tetrafluoroborate **6a** (56 mg, 0.25 mmol). The reaction mixture
31 was stirred at ambient temperature for 0.5 h and then diluted by addition of methanol (6.0 mL).
32 Arene diazonium salt **6e** (68 mg, 0.30 mmol) was then added and the mixture was stirred at
33 ambient temperature for 18 h, evaporated, and the residue was purified by column
34 chromatography on silica using hexanes-ethyl acetate mixtures of increasing polarity to furnish
35 *endo-7ae* (70 mg, 0.17 mmol, 69%): colourless oil; ^1H NMR (500 MHz, CDCl_3) δ 7.46 - 7.41
36 (m, 2H), 7.37 - 7.31 (m, 5H), 7.15 (dm, J = 8.5 Hz, 2H), 7.12 (dm, J = 8.7 Hz, 2H), 6.90 (dm,
37 J = 8.7 Hz, 2H), 6.27 (d, J = 1.6 Hz, 1H), 5.34 (s (br.), 1H), 3.80 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126
38 MHz, CDCl_3) δ 169.4, 169.1, 159.1, 151.7, 138.4, 133.4, 131.5, 130.9, 129.9, 129.7, 129.2,
39 129.1, 129.0, 127.8, 125.8, 114.5, 55.4, 46.7; IR (ATR) ν 1709 (s), 1598 (w), 1490 (m), 1386
40 (m), 1250 (m); HRMS (EI) calcd for $\text{C}_{24}\text{H}_{18}^{35}\text{ClNO}_3$ [M^+] 403.0970, found 403.0978.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3-((4-Methoxyphenyl)(phenyl)methyl)-1-phenyl-1*H*-pyrrole-2,5-dione (*endo-7ka*).

Following the general procedure, *exo-1ak* (66 mg, 0.25 mmol) and **6a** (67 mg, 0.30 mmol) were converted to *endo-7ka* (67 mg, 0.18 mmol, 74%): yellowish solid, mp 139 – 141 °C; ¹H NMR (600 MHz, CDCl₃) δ 7.46 - 7.41 (m, 2H), 7.38 – 7.34 (m, 4H), 7.33 (tt, *J* = 7.5, 1.3 Hz, 1H), 7.29 (tt, *J* = 7.3, 1.3 Hz, 1H), 7.24 – 7.20 (m, 2H), 7.15 (dm, *J* = 8.7 Hz, 2H), 6.90 (dm, *J* = 8.8 Hz, 2H), 6.29 (d, *J* = 1.7 Hz, 1H), 5.38 (s (br.), 1H), 3.80 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 169.6, 169.3, 159.0, 152.2, 139.9, 131.6, 131.5, 129.7, 129.1, 129.0, 129.0, 128.6, 127.8, 127.5, 125.9, 114.4, 55.4, 47.3; IR (ATR) ν 1702 (s), 1513 (m), 1500 (m), 1397 (s), 693 (s); HRMS (EI) calcd for C₂₄H₁₉NO₃ [M⁺] 369.1365, found 369.1364.


3-((4-Methoxyphenyl)(3,4,5-trimethoxyphenyl)methyl)-1-phenyl-1*H*-pyrrole-2,5-dione

(*endo-7ta*). Following the general procedure, *exo-1at* (88 mg, 0.25 mmol) and **6a** (67 mg, 0.30 mmol) were converted to *endo-7ta* (110 mg, 0.24 mmol, 96%): off-white solid, mp 139 – 140 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.46 - 7.40 (m, 2H), 7.37 - 7.30 (m, 3H), 7.15 (dm, *J* = 8.6 Hz, 2H), 6.90 (dm, *J* = 8.8 Hz, 2H), 6.41 (s, 2H), 6.32 (d, *J* = 1.7 Hz, 1H), 5.30 (d, *J* = 1.2 Hz, 1H), 3.84 (s, 3H), 3.80 (s, 9H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 169.6, 169.3, 159.0, 153.6, 152.1, 137.4, 135.4, 131.6, 131.3, 129.6, 129.1, 128.8, 127.8, 125.8, 114.4, 105.8, 61.0, 56.3, 55.4, 47.5; IR (ATR) ν 1702 (s), 1615 (m), 1505 (m), 1399 (m), 1126 (s), 698 (s); HRMS (EI) calcd for C₂₇H₂₅NO₆ [M⁺] 459.1682, found 459.1685.

3-((4-Chlorophenyl)(3,4,5-trimethoxyphenyl)methyl)-1-phenyl-1*H*-pyrrole-2,5-dione

(*endo-7te*). Following the general procedure, *exo-1at* (88 mg, 0.25 mmol) and **6e** (68 mg, 0.30 mmol) were converted to *endo-7te* (110 mg, 0.24 mmol, 95%): yellowish oil; ¹H NMR (600 MHz, CDCl₃) δ 7.46 - 7.40 (m, 2H), 7.38 - 7.31 (m, 5H), 7.17 (dm, *J* = 8.4 Hz, 2H), 6.39 (s, 2H), 6.33 (d, *J* = 1.7 Hz, 1H), 5.32 (d, *J* = 1.0 Hz, 1H), 3.84 (s, 3H), 3.81 (s, 6H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 169.4, 169.0, 153.7, 151.2, 137.9, 137.6, 134.5, 133.6, 131.4, 129.9, 129.3, 129.2, 129.2, 127.9, 125.8, 105.8, 61.0, 56.3, 47.6; IR (ATR) ν 1710 (s), 1590 (m), 1502 (m), 1386 (m), 1125 (s); HRMS (EI) calcd for C₂₆H₂₂³⁵ClNO₅ [M⁺] 463.1181, found 463.1173.

3-((4-Bromophenyl)(3,4,5-trimethoxyphenyl)methyl)-1-phenyl-1H-pyrrole-2,5-dione
(*endo*-7tf).



Following the general procedure, *exo*-1at (88 mg, 0.25 mmol) and **6f** (81 mg, 0.30 mmol) were converted to *endo*-7tf (53 mg, 0.11 mmol, 42%): yellowish oil; ^1H NMR (600 MHz, CDCl_3) δ 7.49 (dm, $J = 8.5$ Hz, 2H, $\text{H}^{18,20}$), 7.45 - 7.42 (m, 2H, $\text{H}^{6,8}$), 7.36 - 7.32 (m, 3H, $\text{H}^{5,7,9}$), 7.11 (dm, $J = 8.3$ Hz, 2H, $\text{H}^{17,21}$), 6.38 (s, 2H, $\text{H}^{11,15}$), 6.33 (d, $J = 1.7$ Hz, 1H, H^1), 5.30 (d, $J = 1.1$ Hz, 1H, H^{27}), 3.84 (s, 3H, H^{23}), 3.81 (s, 6H, $\text{H}^{24,25}$); ^{13}C $\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 169.4 (C^2), 169.0 (C^4), 153.7 ($\text{C}^{12,14}$), 151.1 (C^{26}), 138.4 (C^{16}), 137.6 (C^{13}), 134.4 (C^{10}), 132.2 ($\text{C}^{18,20}$), 131.4 (C^3), 130.2 ($\text{C}^{17,21}$), 129.2 (C^1), 129.2 ($\text{C}^{6,8}$), 127.9 (C^7), 125.8 ($\text{C}^{5,9}$), 121.8 (C^{19}), 105.8 ($\text{C}^{11,15}$), 61.0 (C^{23}), 56.3 ($\text{C}^{24,25}$), 47.7 (C^{27}); IR (ATR) ν 1710 (s), 1593 (m), 1385 (m), 1123 (m), 528 (m); HRMS (EI) calcd for $\text{C}_{26}\text{H}_{22}^{79}\text{BrNO}_5$ [M^+] 507.0676, found 507.0680.


(*E*)-3-((4-Nitrophenyl)(3,4,5-trimethoxyphenyl)methylene)-1-phenylpyrrolidine-2,5-dione ((*E*)-*exo*-7tj) and (*Z*)-3-((4-nitrophenyl)(3,4,5-trimethoxyphenyl)methylene)-1-phenylpyrrolidine-2,5-dione ((*Z*)-*exo*-7tj). Following the general procedure, *exo*-1at (88 mg, 0.25 mmol) and **6j** (71 mg, 0.30 mmol) were converted to a 4 : 1 mixture of (*E*)- and (*Z*)-*exo*-7tj, which was contaminated with minor amounts of unidentified byproducts (107 mg, 0.24 mmol, >90%): yellowish oil. *NMR-data of the major isomer (Z)-exo-7tj, obtained from the mixture:* ^1H NMR (500 MHz, CDCl_3) δ 8.22 (dm, $J = 8.9$ Hz, 2H, CHCNO_2), 7.53 - 7.27 (m, 7H, CHCHCNO_2 , Ph), 6.41 (s, 2H, $\text{C}_6\text{H}_2(\text{OCH}_3)_3$), 3.89 (s, 3H, $p\text{-OCH}_3$), 3.80 (s, 6H, $m\text{-OCH}_3$), 3.73 (s, 2H, $\text{C}(\text{O})\text{CH}_2$); ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 172.1, 167.6, 153.7, 153.1, 150.0, 147.8, 139.5, 145.7, 134.3, 131.7, 130.0, 129.2, 128.8, 126.5, 124.6, 123.5, 122.8, 106.4, 61.1, 56.5, 36.2. *Selected ^1H NMR data of the minor isomer (E)-exo-7tj, obtained from the*

1
2
3 *mixture*: ^1H NMR (500 MHz, CDCl_3) δ 8.29 (dm, $J = 8.9$ Hz, 2H, CHCNO_2), 6.46 (s, 2H,
4
5 $\text{C}_6\text{H}_2(\text{OCH}_3)_3$).

6
7
8 **3-((3-Nitrophenyl)(3,4,5-trimethoxyphenyl)methyl)-1-phenyl-1H-pyrrole-2,5-dione**

9
10 **(endo-7tu)**. Following the general procedure, *exo-1at* (88 mg, 0.25 mmol) and **6u** (71 mg, 0.30
11 mmol) were converted to *endo-7tu* (12 mg, 0.03 mmol, 10%): yellowish oil; ^1H NMR (600
12 MHz, CDCl_3) δ 8.19 (ddd, $J = 7.0, 2.3, 2.3$ Hz, 1H), 8.13 - 8.12 (m, 1H), 7.60 - 7.55 (m, 2H),
13
14 7.47 - 7.43 (m, 2H), 7.37 - 7.33 (m, 3H), 6.40 (s, 2H), 6.38 (d, $J = 1.7$ Hz, 1H), 5.44 (d, $J = 1.5$
15 Hz, 1H), 3.85 (s, 3H), 3.82 (s, 6H); $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 169.2, 168.7, 154.0,
16
17 150.2, 148.7, 141.7, 138.0, 134.5, 133.5, 131.3, 130.1, 129.7, 129.3, 128.1, 125.8, 123.4, 122.9,
18
19 105.9, 61.1, 56.4, 47.9; IR (ATR) ν 1711 (s), 1591 (m), 1529 (s), 1125 (m), 729 (m); HRMS
20
21 (EI) calcd for $\text{C}_{26}\text{H}_{22}\text{N}_2\text{O}_7$ [M^+] 474.1422, found 474.1422.

22
23
24
25
26
27
28
29 **3-((3-Bromo-4-hydroxyphenyl)(3,4,5-trimethoxyphenyl)methyl)-1-phenyl-1H-pyrrole-**
30
31 **2,5-dione (endo-7tr)**.



43 Following the general procedure, *exo-1at* (88 mg, 0.25 mmol) and **6r** (86 mg, 0.30 mmol) were
44 converted to *endo-7tr* (77 mg, 0.15 mmol, 59%): yellowish oil; ^1H NMR (600 MHz, CDCl_3) δ
45 7.46 - 7.41 (m, 2H, $\text{H}^{13,15}$), 7.36 - 7.32 (m, 3H, $\text{H}^{12,14,16}$), 7.32 (d, $J = 2.1$ Hz, 1H, H^{21}), 7.07 (dd,
46
47 $J = 8.5, 2.1$ Hz, 1H, H^{17}), 7.00 (d, $J = 8.4$ Hz, 1H, H^{18}), 6.38 (s, 2H, $\text{H}^{22,26}$), 6.33 (d, $J = 1.7$ Hz,
48
49 1H, H^2), 5.75 (s, 1H, H^{30}), 5.26 (d, $J = 1.2$ Hz, 1H, H^9), 3.84 (s, 3H, H^{28}), 3.81 (s, 6H, $\text{H}^{27,29}$);
50
51
52
53 $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 169.4 (C^3), 169.1 (C^5), 153.7 ($\text{C}^{23,25}$), 151.9 (C^{19}), 151.3
54
55 (C^1), 137.6 (C^{24}), 134.6 (C^{10}), 132.9 (C^{11}), 132.0 (C^{21}), 131.4 (C^8), 129.2 (C^{17}), 129.2 ($\text{C}^{13,15}$),
56
57 129.1 (C^2), 127.9 (C^{14}), 125.8 ($\text{C}^{12,16}$), 116.6 (C^{18}), 110.8 (C^{20}), 105.8 ($\text{C}^{22,26}$), 61.0 (C^{28}), 56.4
58
59
60

(C^{27,29}), 47.1 (C⁹); IR (ATR) ν 3427 (w), 1707 (s), 1493 (m), 907 (s); HRMS (EI) calcd for C₂₆H₂₂⁷⁹BrNO₆ [M⁺] 523.0625, found 523.0643.

Methyl 5-((2,5-dioxo-1-phenyl-2,5-dihydro-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)-methyl)-2-hydroxybenzoate (*endo*-7ts). Following the general procedure, *exo*-1at (88 mg, 0.25 mmol) and 6s (80 mg, 0.30 mmol) were converted to *endo*-7ts (34 mg, 0.07 mmol, 27%): yellowish oil; ¹H NMR (500 MHz, CDCl₃) δ 10.78 (s, 1H), 7.70 (d, *J* = 2.4 Hz, 1H), 7.46 - 7.42 (m, 2H), 7.37 - 7.31 (m, 4H), 7.01 (d, *J* = 8.6 Hz, 1H), 6.38 (s, 2H), 6.34 (d, *J* = 1.7 Hz, 1H), 5.29 (d, *J* = 1.2 Hz, 1H), 3.95 (s, 3H), 3.84 (s, 3H), 3.81 (s, 6H); ¹³C {¹H} NMR (126 MHz, CDCl₃) δ 170.3, 169.5, 169.2, 161.1, 153.8, 151.5, 137.6, 135.8, 134.8, 131.5, 130.0, 129.6, 129.2, 129.0, 128.0, 125.8, 118.6, 112.7, 105.9, 61.0, 56.4, 52.7, 47.4; IR (ATR) $\tilde{\nu}$ 3150 (w), 2940 (w), 1705 (s), 1401 (m), 1126 (s); HRMS (EI) calcd for C₂₈H₂₅NO₈ [M⁺] 503.1580, found 503.1568.

Acknowledgments

We thank Evonik Oxeno for generous donations of solvents and Umicore (Hanau, Germany) for generous donations of catalysts.

Supporting Information Available statement

The Supporting Information is available free of charge on the ACS Publications website at DOI: [10.1021/acs.joc.3c01234](#). Copies of ¹H and ¹³C NMR spectra for all compounds; 2D-NMR-spectra for representative compounds; irradiation spectra, ¹H NMR spectrum and HPLC chromatogram of (*E/Z*)-*exo*-1at after irradiation (PDF).

References and Footnotes

- 1
2
3 (1) Nolan, C. J.; Evans, B. A. J.; Smith, H. J.; Ahmadi, M.; Nicholls, P. J.;
4
5 Hewlins, M. J. E. Inhibitors of Type 2 5 α -Reductase from Human Genital Skin Fibroblasts
6
7 Based on 3-Phenylmethylene Pyrrolidine-2, 5-dione. *Pharm. Sci.* **1997**, *3*, 249-257.
8
9
10 (2) Ahmed, S.; Denison, S. Mechanism based representation of the active site of
11
12 5 α -reductase (5AR). *Bioorg. Med. Chem. Lett.* **1998**, *8*, 2615-2620.
13
14
15 (3) Guarna, A.; Belle, C.; Machetti, F.; Occhiato, E. G.; Payne, A. H.; Cassiani, C.;
16
17 Comerci, A.; Danza, G.; De Bellis, A.; Dini, S.; Marrucci, A.; Serio, M. 19-Nor-10-
18
19 azasteroids: A Novel Class of Inhibitors for Human Steroid 5 α -Reductases 1 and 2. *J. Med.*
20
21 *Chem.* **1997**, *40*, 1112-1129.
22
23
24 (4) Thareja, S. Steroidal 5 α -Reductase Inhibitors: A Comparative 3D-QSAR Study
25
26 Review. *Chem. Rev.* **2015**, *115*, 2883-2894.
27
28
29 (5) Shalaby, E. M.; Girgis, A. S.; Farag, H.; Mabied, A. F.; Fitch, A. N. Synthesis,
30
31 X-ray powder diffraction and DFT calculations of vasorelaxant active 3-
32
33 (arylmethylidene)pyrrolidine-2,5-diones. *RSC Adv.* **2016**, *6*, 112950-112959.
34
35
36 (6) Kalia, D.; Malekar, P. V.; Parthasarathy, M. Exocyclic Olefinic Maleimides:
37
38 Synthesis and Application for Stable and Thiol-Selective Bioconjugation. *Angew. Chem. Int.*
39
40 *Edit.* **2016**, *55*, 1432-1435.
41
42
43 (7) Liu, Y.; Zhang, W. Iridium-Catalyzed Asymmetric Hydrogenation of α -
44
45 Alkylidene Succinimides. *Angew. Chem.-Int. Edit.* **2013**, *52*, 2203-2206.
46
47
48 (8) Song, T.; Li, L.; Zhou, W.; Zheng, Z.-J.; Deng, Y.; Xu, Z.; Xu, L.-W.
49
50 Enantioselective Copper-Catalyzed Azide-Alkyne Click Cycloaddition to Desymmetrization
51
52 of Maleimide-Based Bis(alkynes). *Chem. Eur. J.* **2015**, *21*, 554-558.
53
54
55 (9) Wang, J.; Liu, H.; Fan, Y.; Yang, Y.; Jiang, Z.; Tan, C.-H. Bicyclic Guanidine-
56
57 Catalyzed Direct Asymmetric Allylic Addition of N-Aryl Alkylidene-Succinimides. *Chem.*
58
59 *Eur. J.* **2010**, *16*, 12534-12537.
60

- 1
2
3 (10) Deshmukh, G. B.; Patil, N. S.; Gaikwad, V. B.; Bhole, A. D.; Patil, V. P.
4
5 Synthesis of substituted N-aryl pyrrolo-quinolines and study of their antimicrobial activities.
6
7 *J. Chem. Pharm. Res.* **2014**, *6*, 393-399.
8
9
10 (11) Gailey, R. G.; Zimmer, H. Lichtinduzierte synthese von cumarinen und
11
12 carbostyriren aus N-phenylsuccinimiden. *Tetrahedron Lett.* **1970**, *11*, 2839-2844.
13
14 (12) Haddad, S.; Boudriga, S.; Porzio, F.; Soldera, A.; Askri, M.; Sriram, D.;
15
16 Yogeeswari, P.; Knorr, M.; Rousselin, Y.; Kubicki, M. M. Synthesis of novel
17
18 dispiropyrrrolothiazoles by three-component 1,3-dipolar cycloaddition and evaluation of their
19
20 antimycobacterial activity. *RSC Adv.* **2014**, *4*, 59462-59471.
21
22
23 (13) Haddad, S.; Boudriga, S.; Porzio, F.; Soldera, A.; Askri, M.; Knorr, M.;
24
25 Rousselin, Y.; Kubicki, M. M.; Golz, C.; Strohmann, C. Regio- and Stereoselective Synthesis
26
27 of Spiropyrrrolizidines and Piperazines through Azomethine Ylide Cycloaddition Reaction. *J.*
28
29 *Org. Chem.* **2015**, *80*, 9064-9075.
30
31
32 (14) Haddad, S.; Boudriga, S.; Akhaja, T. N.; Raval, J. P.; Porzio, F.; Soldera, A.;
33
34 Askri, M.; Knorr, M.; Rousselin, Y.; Kubicki, M. M.; Rajani, D. A strategic approach to the
35
36 synthesis of functionalized spirooxindole pyrrolidine derivatives: in vitro antibacterial,
37
38 antifungal, antimalarial and antitubercular studies. *New J. Chem.* **2015**, *39*, 520-528.
39
40
41 (15) Kaur, A.; Kaur, M.; Singh, B. One-pot Regioselective Synthesis of Novel 1-N-
42
43 Methyl-spiro[2,3]oxindole-spiro[3,3]-1"-N-arylpyrrolidine-2",5"-dione-4-arylpyrrolidines
44
45 through Multicomponent 1,3-Dipolar Cycloaddition Reaction of Azomethine Ylide. *J.*
46
47 *Heterocycl. Chem.* **2015**, *52*, 827-833.
48
49
50 (16) Park, H.; Chien, P. N.; Chun, H.-J.; Ryu, S. E. Identification of Potent
51
52 Leukocyte Common Antigen-Related Phosphatase Inhibitors via Structure-Based Virtual
53
54 Screening. *Bull. Kor. Chem. Soc.* **2013**, *34*, 2006-2010.
55
56
57
58
59
60

- 1
2
3 (17) Hedaya, E.; Theodoropoulos, S. The preparation and reactions of stable
4 phosphorus ylides derived from maleic anhydrides, maleimides or isomaleimides.
5
6
7 *Tetrahedron* **1968**, *24*, 2241-2254.
8
9
10 (18) Schirmer, M.-L.; Adomeit, S.; Spannenberg, A.; Werner, T. Novel Base-Free
11 Catalytic Wittig Reaction for the Synthesis of Highly Functionalized Alkenes. *Chem. Eur. J.*
12 **2016**, *22*, 2458-2465.
13
14
15 (19) Jung, S. H.; Kim, J. H.; Lee, J. H. Facile Preparation of
16 Alkylidenesuccinimides from Maleimides via the Phosphoniosilylation Process. *Bull. Kor.*
17 *Chem. Soc.* **2004**, *25*, 1088-1090.
18
19
20 (20) Haval, K. P.; Argade, N. P. General Strategy for the Synthesis of Natural and
21 Unnatural Dialkylmaleic Anhydrides. *J. Org. Chem.* **2008**, *73*, 6936-6938.
22
23
24 (21) Yan, L.; Yang, W.; Li, L.; Shen, Y.; Jiang, Z. A One-pot Green Synthesis of
25 Alkylidenesuccinimides. *Chin. J. Chem.* **2011**, *29*, 1906-1910.
26
27
28 (22) Bayat, M.; Hosseini, S. R.; Asmari, E. Simple synthesis of (E) and (Z)-2-
29 (arylmethylidene)-N-phenyl succinimides via Wittig olefination by using PS-TPP resin.
30 *Phosphorus Sulfur* **2017**, *192*, 98-102.
31
32
33 (23) Wu, Y.; Tai, H.-H.; Cho, H. Synthesis and SAR of thiazolidinedione
34 derivatives as 15-PGDH inhibitors. *Bioorg. Med. Chem.* **2010**, *18*, 1428-1433.
35
36
37 (24) Lim, L. H.; Zhou, J. A challenging Heck reaction of maleimides. *Org. Chem.*
38 *Front.* **2015**, *2*, 775-777.
39
40
41 (25) Schmidt, B.; Wolf, F.; Brunner, H. Styrylsulfonates and -Sulfonamides through
42 Pd-Catalysed Matsuda–Heck Reactions of Vinylsulfonic Acid Derivatives and
43 Arenediazonium Salts. *Eur. J. Org. Chem.* **2016**, 2972-2982.
44
45
46 (26) Schmidt, B.; Wolf, F.; Ehlert, C. Systematic Investigation into the Matsuda–
47 Heck Reaction of α -Methylene Lactones: How Conformational Constraints Direct the β -H-
48 Elimination Step. *J. Org. Chem.* **2016**, *81*, 11235-11249.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (27) Schmidt, B.; Wolf, F. Synthesis of phenylpropanoids via Matsuda-Heck
4 coupling of arene diazonium salts. *J. Org. Chem.* **2017**, *82*, 4386-4395.
5
6
7 (28) Kikukawa, K.; Matsuda, T. Reaction of diazonium salts with transition metals.
8
9
10 1. arylation of olefins with arene diazonium salts catalyzed by zero valent palladium. *Chem.*
11
12 *Lett.* **1977**, 159-162.
13
14 (29) Roglans, A.; Pla-Quintana, A.; Moreno-Mañas, M. Diazonium Salts as
15
16 Substrates in Palladium-Catalyzed Cross-Coupling Reactions. *Chem. Rev.* **2006**, *106*, 4622-
17
18 4643.
19
20
21 (30) Taylor, J. G.; Moro, A. V.; Correia, C. R. D. Evolution and Synthetic
22
23 Applications of the Heck–Matsuda Reaction: The Return of Arenediazonium Salts to
24
25 Prominence. *Eur. J. Org. Chem.* **2011**, 1403-1428.
26
27
28 (31) Felpin, F.-X.; Nassar-Hardy, L.; Le Callonnec, F.; Fouquet, E. Recent
29
30 Advances in the Heck-Matsuda Reaction in Heterocyclic Chemistry. *Tetrahedron* **2011**, *67*,
31
32 2815-2831.
33
34
35 (32) Oger, N.; Le Callonnec, F.; Jacquemin, D.; Fouquet, E.; Le Grogneq, E.;
36
37 Felpin, F.-X. Heck–Matsuda Arylation of Olefins Through a Bicatlytic Approach: Improved
38
39 Procedures and Rationalization. *Adv. Synth. Catal.* **2014**, *356*, 1065-1071.
40
41
42 (33) de Oliveira, J. M.; Angnes, R. A.; Khan, I. U.; Polo, E. C.; Heerdt, G.;
43
44 Servilha, B. M.; Menezes da Silva, V. H.; Braga, A. A. C.; Correia, C. R. D. Enantioselective,
45
46 Noncovalent, Substrate-Directable Heck–Matsuda and Oxidative Heck Arylations of
47
48 Unactivated Five-Membered Carbocyclic Olefins. *Chem. Eur. J.* **2018**, *24*, 11738-11747.
49
50
51 (34) Li, Z.; Tong, R. Asymmetric Total Syntheses of (–)-Hedycoropyrans A and B.
52
53 *J. Org. Chem.* **2017**, *82*, 1127-1135.
54
55
56 (35) Lucks, S.; Brunner, H. In Situ Generated Palladium on Aluminum Phosphate
57
58 as Catalytic System for the Preparation of β,β -Diarylated Olefins by Matsuda–Heck Reaction.
59
60 *Org. Process Res. Dev.* **2017**, *21*, 1835-1842.

1
2
3 (36) Werner, E. W.; Sigman, M. S. Operationally Simple and Highly (E)-Styrenyl-
4 Selective Heck Reactions of Electronically Nonbiased Olefins. *J. Am. Chem. Soc.* **2011**, *133*,
5 9692-9695.
6
7

8
9
10 (37) Di Fabio, R.; Alvaro, G.; Bertani, B.; Donati, D.; Pizzi, D. M.; Gentile, G.;
11 Pentassuglia, G.; Giacobbe, S.; Spada, S.; Ratti, E.; Corsi, M.; Quartaroli, M.; Barnaby, R. J.;
12 Vitulli, G. Chiral tetrahydroquinoline derivatives as potent anti-hyperalgesic agents in animal
13 models of sustained inflammation and chronic neuropathic pain. *Bioorg. Med. Chem. Lett.*
14 **2007**, *17*, 1176-1180.
15
16

17
18
19 (38) de Luna Freire, K. R.; Tormena, C. F.; Coelho, F. Heck Reaction on Morita-
20 Baylis-Hillman Adducts: Diastereoselective Synthesis of Pyrrolizidinones and Pyrrolizidines.
21 *Synlett* **2011**, *22*, 2059-2063.
22
23

24
25 (39) Pyriadi, T. M.; Fraih, M. Synthesis and Polymerization of N-Arylitaconimides:
26 Free Radically and Anionically. *J. Macromol. Sci., Chem.* **1982**, *18*, 159-172.
27
28

29
30 (40) Pyriadi, T. M.; Berzinji, A. S. Synthesis of phenol formaldehyde-containing
31 pendant itaconamic, itaconimide and poly[N-(substituted) itaconimides]. *Des. Monomers*
32 *Polym.* **2003**, *6*, 115-122.
33
34

35
36 (41) Ahire, M. M.; Mhaske, S. B. Synthesis of Succinimide Derivatives by NHC-
37 Catalyzed Stetter Reaction of Aromatic Aldehydes with N-Substituted Itaconimides. *ACS*
38 *Omega* **2017**, *2*, 6598-6604.
39
40

41
42 (42) Beyer, U.; Krüger, M.; Schumacher, P.; Unger, C.; Kratz, F. Synthese von
43 neuen bifunktionellen Maleinimidverbindungen zur Herstellung von
44 Chemoimmunokonjugaten. *Monatsh. Chem.* **1997**, *128*, 91-102.
45
46

47
48 (43) Yasui, S.; Fujii, M.; Kawano, C.; Nishimura, Y.; Shioji, K.; Ohno, A.
49 Mechanism of dediazonation of arenediazonium salts with triphenylphosphine and trialkyl
50 phosphites. Generation of cation radicals from trivalent phosphorus compounds and their
51 reactions. *J. Chem. Soc., Perkin Trans. 2* **1994**, 177-183.
52
53
54
55
56
57
58
59
60

- 1
2
3 (44) Avila, C. M.; Patel, J. S.; Reddi, Y.; Saito, M.; Nelson, H. M.; Shunatona, H.
4
5 P.; Sigman, M. S.; Sunoj, R. B.; Toste, F. D. Enantioselective Heck–Matsuda Arylations
6
7 through Chiral Anion Phase-Transfer of Aryl Diazonium Salts. *Angew. Chem.-Int. Edit.* **2017**,
8
9 *56*, 5806-5811.
10
11
12 (45) Kikukawa, K.; Nagira, K.; Wada, F.; Matsuda, K. Reaction of diazonium salts
13
14 with transition metals. III. Palladium(0) catalyzed arylation of unsaturated compounds with
15
16 arene diazonium salts. *Tetrahedron* **1981**, *37*, 31-36.
17
18
19 (46) Schmidt, B.; Hölter, F.; Berger, R.; Jessel, S. Mizoroki-Heck reactions with 4-
20
21 phenol diazonium salts. *Adv. Synth. Catal.* **2010**, *352*, 2463-2473.
22
23
24 (47) Sabino, A. S.; Machado, A. H. L.; Correia, C. R. D.; Eberlin, M. N. Probing
25
26 the mechanism of the Heck reaction with arene diazonium salts by Electrospray Mass and
27
28 Tandem Mass spectrometry. *Angew. Chem., Int. Edit.* **2004**, *43*, 2514-2518.
29
30
31 (48) Andersson, C. M.; Andersson, M.: Heck Reactions. In *Science of Synthesis:*
32
33 *Cross Coupling and Heck-Type Reactions*; Larhed, M., Ed.; Thieme: Stuttgart, 2013; Vol. 3;
34
35 pp 7-74.
36
37
38 (49) Valkute, T. R.; Aratikatla, E. K.; Gupta, N. A.; Ganga, S.; Santra, M. K.;
39
40 Bhattacharya, A. K. Synthesis and anticancer studies of Michael adducts and Heck arylation
41
42 products of sesquiterpene lactones, zaluzanin D and zaluzanin C from *Vernonia arborea*. *RSC*
43
44 *Adv.* **2018**, *8*, 38289-38304.
45
46
47 (50) Moreno-Mañas, M.; Pleixats, R.; Roglans, A. Stereospecific Preparation of (E)
48
49 and (Z)-3,3-Diarylacrylonitriles by Heck Reaction. *Synlett* **1997**, 1157-1158.
50
51
52 (51) Gürtler, C.; Buchwald, S. L. A Phosphane-Free Catalyst System for the Heck
53
54 Arylation of Disubstituted Alkenes: Application to the Synthesis of Trisubstituted Olefins.
55
56 *Chem. Eur. J.* **1999**, *5*, 3107-3112.
57
58
59 (52) Littke, A. F.; Fu, G. C. A versatile catalyst for Heck reactions of aryl chlorides
60
and aryl bromides under mild conditions. *J. Am. Chem. Soc.* **2001**, *123*, 6989-7000.

1
2
3 (53) Caló, V.; Nacci, A.; Monopoli, A.; Laera, S.; Cioffi, N. Pd Nanoparticles
4 Catalyzed Stereospecific Synthesis of β -Aryl Cinnamic Esters in Ionic Liquids. *J. Org. Chem.*
5 **2003**, *68*, 2929-2933.
6
7

8
9 (54) Botella, L.; Nájera, C. Mono- and β,β -Double-Heck Reactions of α,β -
10 Unsaturated Carbonyl Compounds in Aqueous Media. *J. Org. Chem.* **2005**, *70*, 4360-4369.
11
12

13 (55) Bachmann, D. G.; Wittwer, C. C.; Gillingham, D. G. Stereoselective Heck
14 Reactions with Vinyl Sulfoxides, Sulfides and Sulfones. *Adv. Synth. Catal.* **2013**, *355*, 3703-
15 3707.
16
17

18 (56) Xiao, L.; Zheng, Y.; Xie, Q.; Shao, L. Palladium-Catalyzed Cascade Saegusa-
19 Heck Reaction: Synthesis of β,β -Diarylacroleins from Arylpropanals and Aryl Iodides. *Eur. J.*
20 *Org. Chem.* **2017**, 5880-5883.
21
22

23 (57) Konno, T.; Yamada, S.; Tani, A.; Miyabe, T.; Ishihara, T. A Novel Synthesis
24 of Trifluoromethylated Multi-Substituted Alkenes via Regio- and Stereoselective Heck
25 Reaction of (E)-4,4,4-Trifluoro-1-phenyl-2-buten-1-one. *Synlett* **2006**, 3025-3028.
26
27

28 (58) Cacchi, S.; Fabrizi, G.; Goggiamani, A.; Sferrazza, A. Palladium-Catalyzed
29 Reaction of Arenediazonium Tetrafluoroborates with Methyl 4-Hydroxy-2-butenolate: An
30 Approach to 4-Aryl Butenolides and an Expedient Synthesis of Rubrolide E. *Synlett* **2009**,
31 1277-1280.
32
33

34 (59) Taylor, J. G.; Correia, C. R. D. Stereoselective Synthesis of Unsymmetrical
35 β,β -Diarylacrylates by a Heck-Matsuda Reaction: Versatile Building Blocks for Asymmetric
36 Synthesis of β,β -Diphenylpropanoates, 3-Aryl-indole, and 4-Aryl-3,4-dihydro-quinolin-2-one
37 and Formal Synthesis of (-)-Indatraline. *J. Org. Chem.* **2011**, *76*, 857-869.
38
39

40 (60) Hii, K. K.; Claridge, T. D. W.; Brown, J. M. Intermediates in the
41 Intermolecular, Asymmetric Heck Arylation of Dihydrofurans. *Angew. Chem., Int. Edit.* **1997**,
42 *36*, 984-987.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (61) Larock, R. C.; Leung, W.-Y.; Stolz-Dunn, S. Synthesis of aryl-substituted
4 aldehydes and ketones via palladium-catalyzed coupling of aryl halides and non-allylic
5 unsaturated alcohols. *Tetrahedron Lett.* **1989**, *30*, 6629-6632.
6
7
8
9
10 (62) Jeffery, T. Palladium-catalysed arylation of allylic alcohols: Highly selective
11 synthesis of β -aromatic carbonyl compounds or β -aromatic α,β -unsaturated alcohols.
12
13
14
15 *Tetrahedron Lett.* **1991**, *32*, 2121-2124.
16
17 (63) Wheatley, B. M. M.; Keay, B. A. Use of Deuterium Labeling Studies to
18 Determine the Stereochemical Outcome of Palladium Migrations during an Asymmetric
19 Intermolecular Heck Reaction. *J. Org. Chem.* **2007**, *72*, 7253-7259.
20
21
22
23 (64) Muller, T.; Bräse, S.: Formation of Heterocycles. In *The Mizoroki-Heck*
24 *Reaction*; Oestreich, M., Ed.; Wiley: Chichester, 2009; pp 215-258.
25
26
27 (65) Rauf, W.; Brown, J. M. Reactive intermediates in catalytic alkenylation;
28 pathways for Mizoroki–Heck, oxidative Heck and Fujiwara–Moritani reactions. *Chem.*
29 *Commun.* **2013**, *49*, 8430-8440.
30
31
32
33 (66) Henriksen, S. T.; Tanner, D.; Cacchi, S.; Norrby, P.-O. DFT-Based
34 Explanation of the Effect of Simple Anionic Ligands on the Regioselectivity of the Heck
35 Arylation of Acrolein Acetals. *Organometallics* **2009**, *28*, 6201-6205.
36
37
38
39 (67) Sigman, M. S.; Werner, E. W. Imparting Catalyst Control upon Classical
40 Palladium-Catalyzed Alkenyl C–H Bond Functionalization Reactions. *Acc. Chem. Res.* **2012**,
41 *45*, 874-884.
42
43
44
45 (68) McDermott, J. X.; White, J. F.; Whitesides, G. M. Thermal decomposition of
46 bis(phosphine)platinum(II) metallocycles. *J. Am. Chem. Soc.* **1976**, *98*, 6521-6528.
47
48
49
50 (69) Crabtree, R. H.: *The Organometallic Chemistry of the Transition Metals*; 4th
51 ed.; Wiley: Hoboken, 2005. pp. 199-203.
52
53
54
55 (70) Xu, H.; Hu, C. T.; Wang, X.; Diao, T. Structural Characterization of β -Agostic
56 Bonds in Pd-Catalyzed Polymerization. *Organometallics* **2017**, *36*, 4099-4102.
57
58
59
60

1
2
3 (71) Jutand, A.: Mechanisms of the Mizoroki-Heck Reaction. In *The Mizoroki-Heck*
4 *Reaction*; Oestreich, M., Ed.; Wiley: Chichester, 2009; pp 1-50.

5
6
7 (72) Felpin, F.-X.; Miqueu, K.; Sotiropoulos, J.-M.; Fouquet, E.; Iburguren, O.;
8
9
10 Laudien, J. Room-Temperature, Ligand- and Base-Free Heck Reactions of Aryl Diazonium
11
12 Salts at Low Palladium Loading: Sustainable Preparation of Substituted Stilbene Derivatives.
13
14 *Chem. Eur. J.* **2010**, *16*, 5191-5204.

15
16
17 (73) Susperregui, N.; Miqueu, K.; Sotiropoulos, J.-M.; Le Callonnec, F.; Fouquet,
18
19 E.; Felpin, F.-X. Sustainable Heck–Matsuda Reaction with Catalytic Amounts of Diazonium
20
21 Salts: An Experimental and Theoretical Study. *Chem. Eur. J.* **2012**, *18*, 7210-7218.

22
23
24 (74) Xu, L.; Hilton, M. J.; Zhang, X.; Norrby, P.-O.; Wu, Y.-D.; Sigman, M. S.;
25
26 Wiest, O. Mechanism, Reactivity, and Selectivity in Palladium-Catalyzed Redox-Relay Heck
27
28 Arylations of Alkenyl Alcohols. *J. Am. Chem. Soc.* **2014**, *136*, 1960-1967.

29
30
31 (75) Dang, Y.; Qu, S.; Wang, Z.-X.; Wang, X. A Computational Mechanistic Study
32
33 of an Unprecedented Heck-Type Relay Reaction: Insight into the Origins of Regio- and
34
35 Enantioselectivities. *J. Am. Chem. Soc.* **2014**, *136*, 986-998.

36
37
38 (76) Cameron, D.; Eisler, S. Photoswitchable double bonds: Synthetic strategies for
39
40 tunability and versatility. *J. Phys. Org. Chem.* **2018**, *31*, e3858.

41
42
43 (77) Beharry, A. A.; Woolley, G. A. Azobenzene photoswitches for biomolecules.
44
45 *Chem. Soc. Rev.* **2011**, *40*, 4422-4437.

46
47
48 (78) Moore, J. W.; Pearson, R. G.: *Kinetics and Mechanism*; 3rd ed.; John Wiley
49
50 and Sons: New York, 1981. pp. 49.

51
52
53 (79) Uchiyama, M.; Kobayashi, Y.; Furuyama, T.; Nakamura, S.; Kajihara, Y.;
54
55 Miyoshi, T.; Sakamoto, T.; Kondo, Y.; Morokuma, K. Generation and Suppression of 3-/4-
56
57 Functionalized Benzyne Using Zinc Ate Base (TMP–Zn–ate): New Approaches to
58
59 Multisubstituted Benzenes. *J. Am. Chem. Soc.* **2008**, *130*, 472-480.

- 1
2
3 (80) Goossen, L. J.; Linder, C.; Rodríguez, N.; Lange, P. P. Biaryl and Aryl Ketone
4
5 Synthesis via Pd-Catalyzed Decarboxylative Coupling of Carboxylate Salts with Aryl
6
7 Triflates. *Chem. Eur. J.* **2009**, *15*, 9336-9349.
8
9
10 (81) Schmidt, B.; Berger, R.; Hölter, F. Functionalized alkoxy arene diazonium salts
11
12 from paracetamol. *Org. Biomol. Chem.* **2010**, *8*, 1406-1414.
13
14 (82) Heinrich, M. R.; Blank, O.; Ullrich, D.; Kirschstein, M. Allylation and
15
16 Vinylation of Aryl Radicals Generated from Diazonium Salts. *J. Org. Chem.* **2007**, *72*, 9609-
17
18 9616.
19
20
21 (83) Prechter, A.; Heinrich, M. R. Hydrogen Peroxide and Arenediazonium Salts as
22
23 Reagents for a Radical Beckmann-Type Rearrangement. *Synthesis* **2011**, 1515-1525.
24
25
26 (84) Bonin, H.; Delbrayelle, D.; Demonchaux, P.; Gras, E. Base free aryl coupling
27
28 of diazonium compounds and boronic esters: self-activation allowing an overall highly
29
30 practical process. *Chem. Commun.* **2010**, *46*, 2677-2679.
31
32
33 (85) Erb, W.; Hellal, A.; Albin, M.; Rouden, J.; Blanchet, J. An Easy Route to
34
35 (Hetero)arylboronic Acids. *Chem. Eur. J.* **2014**, *20*, 6608-6612.
36
37
38 (86) Schmidt, B.; Elizarov, N.; Riemer, N.; Hölter, F. Acetamidoarenediazonium
39
40 Salts: Opportunities for Multiple Arene Functionalization. *Eur. J. Org. Chem.* **2015**, 5826-
41
42 5841.
43
44 (87) Polley, A.; Varalaxmi, K.; Jana, R. Palladium-Catalyzed Ortho C–H Arylation
45
46 of Aniline Carbamates with Diazonium Salts under Mild Conditions: Expedient Synthesis of
47
48 Carbazole Alkaloids. *ACS Omega* **2018**, *3*, 14503-14516.
49
50
51 (88) Akram, M. O.; Shinde, P. S.; Chintawar, C. C.; Patil, N. T. Gold(i)-catalyzed
52
53 cross-coupling reactions of aryldiazonium salts with organostannanes. *Org. Biomol. Chem.*
54
55 **2018**, *16*, 2865-2869.
56
57
58 (89) Nguyen, N. H.; Cougnon, C.; Gohier, F. Deprotection of Arenediazonium
59
60 Tetrafluoroborate Ethers with BBr₃. *J. Org. Chem.* **2009**, *74*, 3955-3957.

1
2
3 (90) Yu, Z.-q.; Lv, Y.-w.; Yu, C.-m.; Su, W.-k. Continuous flow reactor for Balz–
4 Schiemann reaction: a new procedure for the preparation of aromatic fluorides. *Tetrahedron*
5 *Lett.* **2013**, *54*, 1261-1263.
6
7

8
9
10 (91) Majchrzak, M. W.; Kotelko, A. Thermolysis of 7-phenyl-2,3,7-
11 triazabicyclo[3.3.0]oct-2-ene-6,8-dione. *J. Heterocycl. Chem.* **1985**, *22*, 1475-1477.
12
13

14 (92) Nascimento-Júnior, N. M.; Mendes, T. C. F.; Leal, D. M.; Corrêa, C. M. N.;
15 Sudo, R. T.; Zapata-Sudo, G.; Barreiro, E. J.; Fraga, C. A. M. Microwave-assisted synthesis
16 and structure–activity relationships of neuroactive pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine
17 derivatives. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 74-77.
18
19
20
21
22

23 (93) Fahmi, M. M.; Mohamed, N. A. N-(Substituted phenyl) itaconimides as
24 organic stabilizers for plasticized poly(vinyl chloride) against photo-degradation. *Polymer*
25 *Degrad. Stabil.* **2007**, *92*, 733-740.
26
27
28
29

30 (94) Balasubramaniyan, V.; Tongare, D. B.; Gosavi, S. S.; Babar, S. M. Formation
31 of phosphoranes from methyl maleanilates and related substrates with triphenylphosphine and
32 their Wittig olefinations with aromatic aldehydes. *Proc. Indian Acad. Sci. (Chem. Sci.)* **1993**,
33 *105*, 265-271.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60